CN101979382A - Aminoindazole derivatives and use thereof as kinase inhibitors - Google Patents
Aminoindazole derivatives and use thereof as kinase inhibitors Download PDFInfo
- Publication number
- CN101979382A CN101979382A CN2010105043043A CN201010504304A CN101979382A CN 101979382 A CN101979382 A CN 101979382A CN 2010105043043 A CN2010105043043 A CN 2010105043043A CN 201010504304 A CN201010504304 A CN 201010504304A CN 101979382 A CN101979382 A CN 101979382A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- indazole
- chloro
- fluoro
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical class C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 title abstract description 13
- 229940043355 kinase inhibitor Drugs 0.000 title description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 5
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 245
- 125000003118 aryl group Chemical group 0.000 claims description 159
- 125000001072 heteroaryl group Chemical group 0.000 claims description 142
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 94
- 229910052736 halogen Inorganic materials 0.000 claims description 91
- 150000002367 halogens Chemical class 0.000 claims description 90
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 86
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 86
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 76
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 claims description 64
- -1 methoxyl group Chemical group 0.000 claims description 59
- 125000003342 alkenyl group Chemical group 0.000 claims description 53
- 125000000304 alkynyl group Chemical group 0.000 claims description 53
- 239000002585 base Substances 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 46
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 40
- 125000000623 heterocyclic group Chemical group 0.000 claims description 38
- 125000003545 alkoxy group Chemical group 0.000 claims description 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 32
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 28
- 239000004202 carbamide Substances 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 125000004043 oxo group Chemical group O=* 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 230000004048 modification Effects 0.000 claims description 20
- 238000012986 modification Methods 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 19
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 150000001408 amides Chemical class 0.000 claims description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 14
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 12
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 11
- 125000002883 imidazolyl group Chemical group 0.000 claims description 11
- 125000002971 oxazolyl group Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- 125000000335 thiazolyl group Chemical group 0.000 claims description 11
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 11
- 229920002554 vinyl polymer Polymers 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- RCFKEIREOSXLET-UHFFFAOYSA-N disulfamide Chemical compound CC1=CC(Cl)=C(S(N)(=O)=O)C=C1S(N)(=O)=O RCFKEIREOSXLET-UHFFFAOYSA-N 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 229940124530 sulfonamide Drugs 0.000 claims description 9
- 239000011737 fluorine Substances 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- CYWROVCCUXWMES-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-(thiophen-3-ylmethyl)-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC=1C=CSC=1 CYWROVCCUXWMES-UHFFFAOYSA-N 0.000 claims description 6
- GWUGKCNMTGZTJR-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[(2-phenyl-1h-imidazol-5-yl)methyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC(N=1)=CNC=1C1=CC=CC=C1 GWUGKCNMTGZTJR-UHFFFAOYSA-N 0.000 claims description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 6
- 208000007530 Essential hypertension Diseases 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 claims description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 6
- 210000000278 spinal cord Anatomy 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- YNOQXGJOLWDVKW-UHFFFAOYSA-N 1-fluoroindazol-3-amine Chemical compound FN1N=C(C2=CC=CC=C12)N YNOQXGJOLWDVKW-UHFFFAOYSA-N 0.000 claims description 5
- 102100027831 14-3-3 protein theta Human genes 0.000 claims description 5
- 208000016097 disease of metabolism Diseases 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 230000026731 phosphorylation Effects 0.000 claims description 5
- 238000006366 phosphorylation reaction Methods 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- BTYMDPGGZZRMIJ-UHFFFAOYSA-N FN1N=C(C2=CC(=CC=C12)C1=CC=CC=C1)N Chemical compound FN1N=C(C2=CC(=CC=C12)C1=CC=CC=C1)N BTYMDPGGZZRMIJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- LXXOVYCAUYTWGY-UHFFFAOYSA-N (6-chloro-7-cyclopropyl-5-phenyl-1h-indazol-3-yl)urea Chemical compound ClC1=C(C=2C=CC=CC=2)C=C2C(NC(=O)N)=NNC2=C1C1CC1 LXXOVYCAUYTWGY-UHFFFAOYSA-N 0.000 claims description 3
- JSHILBLRRYOGGB-UHFFFAOYSA-N (6-chloro-7-ethynyl-5-phenyl-1h-indazol-3-yl)urea Chemical compound C1=C2C(NC(=O)N)=NNC2=C(C#C)C(Cl)=C1C1=CC=CC=C1 JSHILBLRRYOGGB-UHFFFAOYSA-N 0.000 claims description 3
- AMFLEFQJADZIFY-UHFFFAOYSA-N (6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)urea Chemical compound C1=C2C(NC(=O)N)=NNC2=C(F)C(Cl)=C1C1=CC=CC=C1 AMFLEFQJADZIFY-UHFFFAOYSA-N 0.000 claims description 3
- ROQMDGBDGQPXLS-UHFFFAOYSA-N (6-chloro-7-hydroxy-5-phenyl-1h-indazol-3-yl)urea Chemical compound C1=C2C(NC(=O)N)=NNC2=C(O)C(Cl)=C1C1=CC=CC=C1 ROQMDGBDGQPXLS-UHFFFAOYSA-N 0.000 claims description 3
- XIUJWWJXLQJGGW-UHFFFAOYSA-N (6-chloro-7-methyl-5-phenyl-1h-indazol-3-yl)urea Chemical compound C=1C=2C(NC(N)=O)=NNC=2C(C)=C(Cl)C=1C1=CC=CC=C1 XIUJWWJXLQJGGW-UHFFFAOYSA-N 0.000 claims description 3
- HDWRLGYRWMMCFL-UHFFFAOYSA-N (6-chloro-7-nitro-5-phenyl-1h-indazol-3-yl)urea Chemical compound C1=C2C(NC(=O)N)=NNC2=C([N+]([O-])=O)C(Cl)=C1C1=CC=CC=C1 HDWRLGYRWMMCFL-UHFFFAOYSA-N 0.000 claims description 3
- ZWZRIAJIBBGYGD-UHFFFAOYSA-N (7-amino-6-chloro-5-phenyl-1h-indazol-3-yl)urea Chemical compound C1=C2C(NC(=O)N)=NNC2=C(N)C(Cl)=C1C1=CC=CC=C1 ZWZRIAJIBBGYGD-UHFFFAOYSA-N 0.000 claims description 3
- JICVPALOSNYWEZ-UHFFFAOYSA-N 1-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-3-(4-fluorophenyl)urea Chemical compound C1=CC(F)=CC=C1NC(=O)NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 JICVPALOSNYWEZ-UHFFFAOYSA-N 0.000 claims description 3
- JYFHFEUQMUJMKB-UHFFFAOYSA-N 1-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-3-(4-phenoxyphenyl)urea Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 JYFHFEUQMUJMKB-UHFFFAOYSA-N 0.000 claims description 3
- HFYKTGRJQIRDSK-UHFFFAOYSA-N 1-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-3-[4-(trifluoromethyl)phenyl]urea Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC(=O)NC1=CC=C(C(F)(F)F)C=C1 HFYKTGRJQIRDSK-UHFFFAOYSA-N 0.000 claims description 3
- YZEPSQOOWQJDOM-UHFFFAOYSA-N 1-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-3-cyclohexylurea Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC(=O)NC1CCCCC1 YZEPSQOOWQJDOM-UHFFFAOYSA-N 0.000 claims description 3
- OWLAYDWSJUVPRH-UHFFFAOYSA-N 1-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-3-phenylurea Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC(=O)NC1=CC=CC=C1 OWLAYDWSJUVPRH-UHFFFAOYSA-N 0.000 claims description 3
- PTWMDLYOXULVRR-UHFFFAOYSA-N 1-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-3-prop-2-enylurea Chemical compound C=1C=2C(NC(=O)NCC=C)=NNC=2C(F)=C(Cl)C=1C1=CC=CC=C1 PTWMDLYOXULVRR-UHFFFAOYSA-N 0.000 claims description 3
- MXPKWWZRGFOGRZ-UHFFFAOYSA-N 1-benzyl-3-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)urea Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC(=O)NCC1=CC=CC=C1 MXPKWWZRGFOGRZ-UHFFFAOYSA-N 0.000 claims description 3
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 claims description 3
- AIDLAEPHWROGFI-UHFFFAOYSA-N 2-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=C(C(O)=O)C=CC=C1C(O)=O AIDLAEPHWROGFI-UHFFFAOYSA-N 0.000 claims description 3
- FPFGVNILENOJOY-UHFFFAOYSA-N 4-[[(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)amino]methyl]benzonitrile Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC=C(C#N)C=C1 FPFGVNILENOJOY-UHFFFAOYSA-N 0.000 claims description 3
- IHNUOZRIAVCJOM-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-(1h-pyrazol-5-ylmethyl)-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC=1C=CNN=1 IHNUOZRIAVCJOM-UHFFFAOYSA-N 0.000 claims description 3
- YYZLKBGBJGGQOH-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-(2,3,5,6-tetrafluorophenyl)-1h-indazol-3-amine Chemical compound FC1=CC(F)=C(F)C(NC=2C3=CC(=C(Cl)C(F)=C3NN=2)C=2C=CC=CC=2)=C1F YYZLKBGBJGGQOH-UHFFFAOYSA-N 0.000 claims description 3
- MHQVDMYILIWXGX-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-(2-phenylethyl)-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCCC1=CC=CC=C1 MHQVDMYILIWXGX-UHFFFAOYSA-N 0.000 claims description 3
- SBFSKKSNVCBBQF-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-(2-piperidin-1-ylethyl)-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCCN1CCCCC1 SBFSKKSNVCBBQF-UHFFFAOYSA-N 0.000 claims description 3
- KDQYDFJWBHKKJB-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-(2h-pyridin-1-yl)-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NN1CC=CC=C1 KDQYDFJWBHKKJB-UHFFFAOYSA-N 0.000 claims description 3
- GRISVLJSDMYRKS-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-(3-phenylpropyl)-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCCCC1=CC=CC=C1 GRISVLJSDMYRKS-UHFFFAOYSA-N 0.000 claims description 3
- ZEDYLMKERPVWOX-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-(4,4,4-trifluorobutyl)-1h-indazol-3-amine Chemical compound C=1C=2C(NCCCC(F)(F)F)=NNC=2C(F)=C(Cl)C=1C1=CC=CC=C1 ZEDYLMKERPVWOX-UHFFFAOYSA-N 0.000 claims description 3
- QBRXHJYESZMZNF-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[(5-thiophen-2-ylthiophen-2-yl)methyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC(S1)=CC=C1C1=CC=CS1 QBRXHJYESZMZNF-UHFFFAOYSA-N 0.000 claims description 3
- UWQMTYCIFOTNBA-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[3-(trifluoromethyl)phenyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC1=CC=CC(C(F)(F)F)=C1 UWQMTYCIFOTNBA-UHFFFAOYSA-N 0.000 claims description 3
- SMPISFVMHOVUTG-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[4-(trifluoromethyl)phenyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC1=CC=C(C(F)(F)F)C=C1 SMPISFVMHOVUTG-UHFFFAOYSA-N 0.000 claims description 3
- SADVHEXWFHVSGZ-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[[3-(trifluoromethyl)phenyl]methyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC=CC(C(F)(F)F)=C1 SADVHEXWFHVSGZ-UHFFFAOYSA-N 0.000 claims description 3
- FZAZWOKCOXATOA-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[[4-(trifluoromethoxy)phenyl]methyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC=C(OC(F)(F)F)C=C1 FZAZWOKCOXATOA-UHFFFAOYSA-N 0.000 claims description 3
- NBQAORFEWFDVIT-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[[4-(trifluoromethyl)phenyl]methyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC=C(C(F)(F)F)C=C1 NBQAORFEWFDVIT-UHFFFAOYSA-N 0.000 claims description 3
- ZGCZYOYGTFTZRD-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-pyridin-2-yl-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC1=CC=CC=N1 ZGCZYOYGTFTZRD-UHFFFAOYSA-N 0.000 claims description 3
- FZCVVILJVFSYKS-UHFFFAOYSA-N 6-chloro-7-fluoro-n-(1h-imidazol-5-ylmethyl)-5-phenyl-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CNC=N1 FZCVVILJVFSYKS-UHFFFAOYSA-N 0.000 claims description 3
- SPYHINSEACAYOX-UHFFFAOYSA-N 6-chloro-7-fluoro-n-(2-morpholin-4-ylethyl)-5-phenyl-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCCN1CCOCC1 SPYHINSEACAYOX-UHFFFAOYSA-N 0.000 claims description 3
- WVFXPMGBBXCFSE-UHFFFAOYSA-N 6-chloro-7-fluoro-n-(3-nitrophenyl)-5-phenyl-1h-indazol-3-amine Chemical compound [O-][N+](=O)C1=CC=CC(NC=2C3=CC(=C(Cl)C(F)=C3NN=2)C=2C=CC=CC=2)=C1 WVFXPMGBBXCFSE-UHFFFAOYSA-N 0.000 claims description 3
- WOWBSBNPXHUTNL-UHFFFAOYSA-N 6-chloro-7-fluoro-n-(4-fluorophenyl)-5-phenyl-1h-indazol-3-amine Chemical compound C1=CC(F)=CC=C1NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 WOWBSBNPXHUTNL-UHFFFAOYSA-N 0.000 claims description 3
- QQBGMAYQSPIPJP-UHFFFAOYSA-N 6-chloro-7-fluoro-n-(4-nitrophenyl)-5-phenyl-1h-indazol-3-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 QQBGMAYQSPIPJP-UHFFFAOYSA-N 0.000 claims description 3
- XBKWINYBXXUBSG-UHFFFAOYSA-N 6-chloro-7-fluoro-n-[(1-methylindol-3-yl)methyl]-5-phenyl-1h-indazol-3-amine Chemical compound C12=CC=CC=C2N(C)C=C1CNC(C1=C2)=NNC1=C(F)C(Cl)=C2C1=CC=CC=C1 XBKWINYBXXUBSG-UHFFFAOYSA-N 0.000 claims description 3
- HZUBMNKUVOYSMW-UHFFFAOYSA-N 6-chloro-7-fluoro-n-[(4-fluorophenyl)methyl]-5-phenyl-1h-indazol-3-amine Chemical compound C1=CC(F)=CC=C1CNC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 HZUBMNKUVOYSMW-UHFFFAOYSA-N 0.000 claims description 3
- WWBVBGHXCLXVIJ-UHFFFAOYSA-N 6-chloro-7-fluoro-n-[3-fluoro-5-(trifluoromethyl)phenyl]-5-phenyl-1h-indazol-3-amine Chemical compound FC(F)(F)C1=CC(F)=CC(NC=2C3=CC(=C(Cl)C(F)=C3NN=2)C=2C=CC=CC=2)=C1 WWBVBGHXCLXVIJ-UHFFFAOYSA-N 0.000 claims description 3
- MJVVAPIMVIOCML-UHFFFAOYSA-N 6-chloro-7-fluoro-n-[[3-(4-methylphenoxy)phenyl]methyl]-5-phenyl-1h-indazol-3-amine Chemical compound C1=CC(C)=CC=C1OC1=CC=CC(CNC=2C3=CC(=C(Cl)C(F)=C3NN=2)C=2C=CC=CC=2)=C1 MJVVAPIMVIOCML-UHFFFAOYSA-N 0.000 claims description 3
- PIVASUNDSBJKLZ-UHFFFAOYSA-N 6-chloro-n-(cyclohexylmethyl)-7-fluoro-5-phenyl-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1CCCCC1 PIVASUNDSBJKLZ-UHFFFAOYSA-N 0.000 claims description 3
- XAVYROIPSPMYJI-UHFFFAOYSA-N 6-chloro-n-(cyclopentylmethyl)-7-fluoro-5-phenyl-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1CCCC1 XAVYROIPSPMYJI-UHFFFAOYSA-N 0.000 claims description 3
- UJOQQEBRWVMGIJ-UHFFFAOYSA-N 6-chloro-n-(cyclopropylmethyl)-7-fluoro-5-phenyl-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1CC1 UJOQQEBRWVMGIJ-UHFFFAOYSA-N 0.000 claims description 3
- RKZFJYHLNSEASB-UHFFFAOYSA-N 6-chloro-n-[(4-chloro-3-fluorophenyl)methyl]-7-fluoro-5-phenyl-1h-indazol-3-amine Chemical compound C1=C(Cl)C(F)=CC(CNC=2C3=CC(=C(Cl)C(F)=C3NN=2)C=2C=CC=CC=2)=C1 RKZFJYHLNSEASB-UHFFFAOYSA-N 0.000 claims description 3
- IXSFRRMIUBJQNY-UHFFFAOYSA-N 6-chloro-n-[[4-(dimethylamino)phenyl]methyl]-7-fluoro-5-phenyl-1h-indazol-3-amine Chemical compound C1=CC(N(C)C)=CC=C1CNC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 IXSFRRMIUBJQNY-UHFFFAOYSA-N 0.000 claims description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 3
- MVWQEHAJUXTJBU-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NC1=CC=C(C=C1)CN)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NC1=CC=C(C=C1)CN)C1=CC=CC=C1 MVWQEHAJUXTJBU-UHFFFAOYSA-N 0.000 claims description 3
- AYDQIZKZTQHYIY-UHFFFAOYSA-N OC(=O)C1(C)CC(C(O)=O)=CC=C1 Chemical compound OC(=O)C1(C)CC(C(O)=O)=CC=C1 AYDQIZKZTQHYIY-UHFFFAOYSA-N 0.000 claims description 3
- APWPIIIDXNQVPS-UHFFFAOYSA-N [6-chloro-5-phenyl-7-(trifluoromethoxy)-1h-indazol-3-yl]urea Chemical compound C1=C2C(NC(=O)N)=NNC2=C(OC(F)(F)F)C(Cl)=C1C1=CC=CC=C1 APWPIIIDXNQVPS-UHFFFAOYSA-N 0.000 claims description 3
- RPJRXYPOLGQFBW-UHFFFAOYSA-N [6-chloro-5-phenyl-7-(trifluoromethyl)-1h-indazol-3-yl]urea Chemical compound C1=C2C(NC(=O)N)=NNC2=C(C(F)(F)F)C(Cl)=C1C1=CC=CC=C1 RPJRXYPOLGQFBW-UHFFFAOYSA-N 0.000 claims description 3
- QYZDAGHVHVRHOT-UHFFFAOYSA-N [6-chloro-7-(dimethylamino)-5-phenyl-1h-indazol-3-yl]urea Chemical compound C=1C=2C(NC(N)=O)=NNC=2C(N(C)C)=C(Cl)C=1C1=CC=CC=C1 QYZDAGHVHVRHOT-UHFFFAOYSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- DVRDILWFWFFCIU-UHFFFAOYSA-N n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-4-fluorobenzenesulfonamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 DVRDILWFWFFCIU-UHFFFAOYSA-N 0.000 claims description 3
- OJDJRGHUQLRSLC-UHFFFAOYSA-N n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-5-(1,2-oxazol-3-yl)thiophene-2-sulfonamide Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NS(=O)(=O)C(S1)=CC=C1C=1C=CON=1 OJDJRGHUQLRSLC-UHFFFAOYSA-N 0.000 claims description 3
- QSABSXVSSUNPOJ-UHFFFAOYSA-N n-[4-[[(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)amino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 QSABSXVSSUNPOJ-UHFFFAOYSA-N 0.000 claims description 3
- SFLWTZAESDGCAY-UHFFFAOYSA-N n-benzyl-6-chloro-7-fluoro-5-phenyl-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC=CC=C1 SFLWTZAESDGCAY-UHFFFAOYSA-N 0.000 claims description 3
- YPKFLCNLGPOPCN-UHFFFAOYSA-N n-butyl-6-chloro-7-fluoro-5-phenyl-1h-indazol-3-amine Chemical compound C1=C2C(NCCCC)=NNC2=C(F)C(Cl)=C1C1=CC=CC=C1 YPKFLCNLGPOPCN-UHFFFAOYSA-N 0.000 claims description 3
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 3
- 208000013044 corticobasal degeneration disease Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 abstract description 4
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 102000020233 phosphotransferase Human genes 0.000 abstract description 3
- 235000002639 sodium chloride Nutrition 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 229960001866 silicon dioxide Drugs 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 229910052763 palladium Inorganic materials 0.000 description 8
- 239000012043 crude product Substances 0.000 description 7
- 230000006837 decompression Effects 0.000 description 7
- 238000001819 mass spectrum Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000011097 chromatography purification Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000000247 postprecipitation Methods 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 239000012429 reaction media Substances 0.000 description 5
- 0 *c(c(*)c1*)cc2c1[n]nc2N* Chemical compound *c(c(*)c1*)cc2c1[n]nc2N* 0.000 description 4
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 3
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- NYWDAFSXGHUQLQ-UHFFFAOYSA-N 6-chloro-7-fluoro-n-[(5-methylfuran-2-yl)methyl]-5-phenyl-1h-indazol-3-amine Chemical compound O1C(C)=CC=C1CNC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 NYWDAFSXGHUQLQ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VZDVDCYDBJSUNG-UHFFFAOYSA-N CCCCN.CCCCN.CCCCN.N Chemical compound CCCCN.CCCCN.CCCCN.N VZDVDCYDBJSUNG-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006277 sulfonation reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical group C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 238000007125 Buchwald synthesis reaction Methods 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 238000011672 OFA rat Methods 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- QMBLSTVROSNRNI-UHFFFAOYSA-N [chloro(ethoxy)methyl]silane Chemical compound [SiH3]C(OCC)Cl QMBLSTVROSNRNI-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 150000001638 boron Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical class ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- IDIOJRGTRFRIJL-UHFFFAOYSA-N iodosilane Chemical compound I[SiH3] IDIOJRGTRFRIJL-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000004355 nitrogen functional group Chemical group 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- USISRUCGEISZIB-UHFFFAOYSA-N piperidin-3-one Chemical compound O=C1CCCNC1 USISRUCGEISZIB-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- QGKLPGKXAVVPOJ-UHFFFAOYSA-N pyrrolidin-3-one Chemical compound O=C1CCNC1 QGKLPGKXAVVPOJ-UHFFFAOYSA-N 0.000 description 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- ALZJERAWTOKHNO-UHFFFAOYSA-M sodium;dodecyl sulfate;3-morpholin-4-ylpropane-1-sulfonic acid Chemical compound [Na+].OS(=O)(=O)CCCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O ALZJERAWTOKHNO-UHFFFAOYSA-M 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention relates to novel aminoindazole derivatives having general formula (I) and to the use thereof for the treatment of diseases that can result from abnormal kinase activity.
Description
The application is the Chinese invention patent application (applying date: on September 3rd, 2003; Application number: 038256169 (international application no: PCT/FR2003/002634); Denomination of invention: Aminoindazole derivatives and as the purposes of kinase inhibitor) divide an application.
The present invention relates to formula (I) derivative:
Or its pharmacologically acceptable salt is as the purposes of kinase inhibitor.
Theme of the present invention is to utilize formula (I) Aminoindazole derivatives and pharmacologically acceptable salt thereof to prepare the pharmaceutical composition that expection is used to prevent and treats the disease that may be caused by abnormal kinase, for example, described disease relates to neurodegenerative disease, Alzheimer, Parkinson's disease, os frontoparietale (frontoparietal) dementia, corticobasal degeneration, Pick's disease, apoplexy, cranium and trauma of spinal cord and peripheral neuropathy, obesity, metabolic disease, type ii diabetes, essential hypertension, atherosclerotic cardiovascular disease, polycystic ovary syndrome, X syndrome, immune deficiency and cancer, this pharmaceutical composition comprise new Aminoindazole derivatives and pharmacologically acceptable salt and new Aminoindazole derivatives and pharmacologically acceptable salt thereof.
Described among the patent application WO 02/074388 and be (a) type Aminoindazole derivatives of potassium channel activator:
Wherein G is
Z is NX0, S or O;
E is N or CX1;
Y is halogen, X2 or OX2;
X0, X1 and X2 are the alkyl of halogen, alkyl or replacement;
A, B and D be hydrogen, halogen, replacement or unsubstituted alkyl, C (O)
pR13, C (O) NR13R14, SO
2NR13, R14, S (O)
pR15, OR15 or NR13R14;
P is the 0-2 integer;
R13 and R14 are hydrogen, replacement or unsubstituted alkyl, replacement or unsubstituted cycloalkyl, replacement or unsubstituted heteroaryl, replacement or unsubstituted heterocycle, replacement or unsubstituted assorted alkyl, replacement or unsubstituted heteroaryl-assorted alkyl or replace or unsubstituted aryl-assorted alkyl;
R15 for that replace or unsubstituted alkyl, replacement or unsubstituted cycloalkyl, replacement or unsubstituted heteroaryl, replacement or unsubstituted heterocycle, replacement or unsubstituted assorted alkyl, replacement or unsubstituted heteroaryl-assorted alkyl or replace or unsubstituted aryl-assorted alkyl.
The present invention relates to formula (I) derivative as giving a definition, wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1, C (=NH) R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, heterocycle, formyl radical, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5, R6 and R7 are independently from each other following groups: halogen, CN, NO2, NH
2, OH, COOH, C (O) OR8 ,-O-C (O) R8, NR8R9, NHC (O) R8, C (O) NR8R9, NHC (S) R8, C (S) NR8R9, SR8, S (O) R8, SO
2R8, NHSO
2R8, SO
2NR8R9 ,-O-SO
2R8 ,-SO
2-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C) alkyl, (1-6C) alkoxyl group, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl group, adamantyl or multi-ring alkyl; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
R1, R2, R8, R9, R10 and R11 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group, heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, trifluoromethyl, trifluoromethoxy;
R1 and R2 or R8 and R9 or R10 and R11 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
And when R3 was 6-membered nitrogen-containing heteroaryl base or thiazolyl or imidazolyl Huo oxazolyl, at least one was an aryl unsubstituted or that replaced by one or more substituting groups in R5 and the R6 base, and described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
Especially, the present invention relates to formula (I) derivative as giving a definition, wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1, C (=NH) R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, heterocycle, formyl radical, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5 and R6 are independently from each other following groups: halogen, CN, NO
2, NH
2, OH, COOH, C (O) OR8 ,-O-C (O) R8, NR8R9, NHC (O) R8, C (O) NR8R9, NHC (S) R8, C (S) NR8R9, SR8, S (O) R8, SO
2R8, NHSO
2R8, SO
2NR8R9 ,-O-SO
2R8 ,-SO
2-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C) alkyl, (1-6C) alkoxyl group, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl group, adamantyl, multi-ring alkyl; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
R7 is halogen, methyl, cyclopropyl, CN, OH, methoxyl group, trifluoromethyl, vinyl, ethynyl, trifluoromethoxy, NO
2, NH
2Or NMe
2
R1, R2, R8, R9, R10 and R11 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, trifluoromethyl or trifluoromethoxy;
R1 and R2 or R8 and R9 or R10 and R11 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
And when R3 was 6-membered nitrogen-containing heteroaryl base or thiazolyl, imidazolyl Huo oxazolyl, at least one was an aryl unsubstituted or that replaced by one or more substituting groups in R5 and the R6 base, and described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy and (1-6C) alkyl;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
The present invention preferably relates to as the formula of giving a definition (I) derivative, wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, formyl radical, oxo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5 is an aryl;
R6 and R7 are halogen, methyl, cyclopropyl, CN, OH, methoxyl group, trifluoromethyl, vinyl, ethynyl, trifluoromethoxy, NO independently of one another
2, NH
2Or NMe
2
R1 and R2 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy;
R1 and R2 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
The present invention preferably relates to as the formula of giving a definition (I) derivative, wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, formyl radical, oxo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5 is an aryl;
R6 is halogen, methyl, cyclopropyl, CN, OH, methoxyl group, trifluoromethyl, vinyl, ethynyl, trifluoromethoxy, NO
2, NH
2Or NMe
2
R7 is a halogen;
R1 and R2 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy;
R1 and R2 can form 5-or the 6-unit ring that does not contain or contain heteroatoms such as O, S or N;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
In contextual definition, (1-6C) alkyl comprises 1-6 straight or branched carbon atom; Alkenyl comprises 2-6 straight or branched carbon atom and 1-3 conjugated or unconjugated pair of key; Alkynyl group comprises 2-6 straight or branched carbon atom and 1-3 conjugated or unconjugated triple bond; Aryl is selected from phenyl, naphthyl or indenyl; Heteroaryl comprises 3-10 ring members, do not comprise or comprise one or more heteroatomss that are selected from oxygen, sulphur and nitrogen, particularly, thiazolyl, thienyl, pyrryl, pyridyl, furyl, imidazolyl, oxazolyl, pyrazinyl, tetrazyl, oxadiazole base, thiadiazolyl group, Yi oxadiazole base, different thiadiazolyl group, isothiazolyl, isoxazolyl, triazolyl, pyrazolyl or indyl; Halogen radical is chlorine, iodine, fluorine or bromine; Multi-ring alkyl is selected from adamantyl, quinuclidinyl, Camphanyl, norcamphane base, borneol thiazolinyl or norbornene; The heteroaryl Cycloalkylfused with (1-10C) is selected from indanyl, isochroman base, chromanyl, 1,2,3,4-tetrahydro isoquinolyl or 1,2,3,4-tetrahydric quinoline group; Heterocyclic radical comprises 1-2 and is selected from the heteroatoms of oxygen, sulphur or nitrogen and is expressed as piperidyl, morpholinyl, pyrrolidyl, imidazolidyl, pyrazolidyl, isothiazole alkyl, thiazolidyl, isoxazole alkyl, oxazolidinyl, piperazinyl, azetidinyl, 2-piperidone, 3-piperidone, 4-piperidone, 2-Pyrrolidone or 3-pyrrolidone especially.
Formula (I) compound has one or more unsymmetrical carbons, therefore may exist with isomers, racemic modification, enantiomer and diastereomeric form; The latter comprises that its mixture also constitutes part of the present invention.
The formula of using among the present invention (I) compound can be mentioned following compounds:
N-(two the ring [2.2.1] heptan-5-alkene-2-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3, the 3-dimethylbutyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3-phenyl propyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(cyclopropyl methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(cyclopentyl-methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-(methylthio group) propyl group]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(phenylethyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(cyclohexyl methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-propyl group-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(2,2,3,3,4,4,4-seven fluorine butyl)-5-phenyl-1H-indazole-3-amine hydrate;
6-chloro-7-fluoro-N-(4,4,4-trifluoro butyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(4-p-methoxy-phenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(phenyl methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(4-cyano-phenyl) methyl]-5-phenyl-1H-indazole-3-amine;
The N-[(4-chloro-phenyl-) methyl]-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(3-p-methoxy-phenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[4-(trifluoromethoxy) phenyl] methyl]-5-phenyl-1H-indazole-3-amine;
N-[4-[[[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] amino] methyl] phenyl] ethanamide;
6-chloro-7-fluoro-N-[(3, the 5-dichlorophenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[4-(trifluoromethyl) phenyl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(4-fluorophenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-(4-methylphenoxy) phenyl methyl]-5-phenyl-1H-indazole-3-amine;
N-(2,2,3,3,4,4,4-seven fluorine butyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[3, two (trifluoromethyl) phenyl of 5-] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[3-(trifluoromethyl) phenyl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(6-methoxyl group-2-naphthyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(pentafluorophenyl group) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[4-(methylthio group) phenyl] methyl]-5-phenyl-1H-indazole-3-amine;
N-[(4-chloro-3-fluorophenyl) methyl]-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(3,3, the 3-trifluoro propyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(3-thienyl methyl)-1H-indazole-3-amine;
N-(two the ring [2.2.1] heptan-5-alkene-2-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
N-(1,1 '-xenyl-4-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[4-(dimethylamino) phenyl] methyl]-5-phenyl-1H-indazole-3-amine;
N-(2,2 '-bithiophene-5-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[1-(phenyl methyl)-1H-imidazoles-2-yl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[1-methyl isophthalic acid H-imidazoles-2-yl] methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(1-Methyl-1H-indole-3-yl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(5-methyl-2-furyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(1H-pyrroles-2-ylmethyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[(1H-imidazoles-2-yl) methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[(1H-imidazol-4 yl) methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(1H-pyrazole-3-yl methyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[2-methyl isophthalic acid H-imidazol-4 yl] methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(3,5-dimethyl-1-phenyl-1H-pyrazoles-4-yl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[2-phenyl-1H-imidazol-4 yl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[5-(4-chloro-phenyl-)-2-furyl] methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[(1-methyl isophthalic acid H-pyrroles-2-yl) methyl]-1H-indazole-3-amine;
4-[5-[[[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] amino] methyl]-the 2-furyl]-benzsulfamide;
6-chloro-7-fluoro-5-phenyl-N-(3-thienyl methyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[2-phenyl-1H-imidazol-4 yl] methyl]-1H-indazole-3-amine;
2-[[[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] amino] methyl]-5-(methylthio group)-1H-imidazoles-4-ethyl formate;
6-chloro-7-fluoro-5-phenyl-N-[[5-[4-(trifluoromethyl) phenyl]-the 2-furyl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[2-(piperidino) ethyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[2-(4-morpholinyl) ethyl]-5-phenyl-1H-indazole-3-amine;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(3, the 5-dichlorophenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(2-propenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(phenyl methyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-Phenoxyphenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-p-methoxy-phenyl) methyl] urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-[4-(trifluoromethyl) phenyl] urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-p-methoxy-phenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-cyclohexyl urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-propyl group urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-chloro-phenyl-) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-fluorophenyl) urea;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-N '-(three ring [3.3.1.1
3,7] last of the ten Heavenly stems)-1-base urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-aminomethyl phenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-methyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-cyano group-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-cyclopropyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-hydroxyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-methoxyl group-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-trifluoromethyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-trifluoromethoxy-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-nitro-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-amino-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-dimethylamino-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-ethynyl-5-phenyl-1H-indazole-3-yl) urea;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-methyl-benzsulfamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] Toluidrin;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-2-third sulphonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-2,2,2-trifluoro ethyl sulfonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-the 2-thiophenesulfonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] benzsulfamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-(trifluoromethyl) benzsulfamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-5-(3-isoxazolyl)-2-thiophenesulfonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-fluorobenzene sulphonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-the 4-methoxybenzenesulphoismide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] the benzene Toluidrin;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-1-methyl isophthalic acid H-imidazoles-4-sulphonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-(1, the 1-dimethyl ethyl) benzsulfamide;
N-[4-[[(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl) amino] alkylsulfonyl] phenyl] ethanamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-methylbenzene Toluidrin;
6-chloro-7-fluoro-N-(pentafluorophenyl group)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3, the 4-difluorophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(2,3,5,6-tetrafluoro phenyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(2,4, the 6-trifluorophenyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(4-fluorophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-(trifluoromethyl) phenyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[4-(trifluoromethyl) phenyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-fluoro-5-(trifluoromethyl) phenyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(4-nitrophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3-nitrophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3-p-methoxy-phenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(4-p-methoxy-phenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N, 5-phenylbenzene-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(1-pyridyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(2-pyridyl)-5-phenyl-1H-indazole-3-amine;
N-butyl-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-phenylurea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-3-methoxybenzenesulphoismide;
Its isomer, its mixture, its racemic modification, enantiomer, diastereomer or tautomer and pharmacologically acceptable salt thereof.
And following compounds especially:
Piperidines-1-formic acid (6,7-two fluoro-5-phenyl-1H-indazole-3-yl) acid amides;
Tetramethyleneimine-1-formic acid (6,7-two fluoro-5-phenyl-1H-indazole-3-yl) acid amides;
1-(6,7-two fluoro-5-phenyl-1H-indazole-3-yl)-3-[3-(4-methylpiperazine-1-yl) propyl group] urea;
N-(6,7-two fluoro-5-phenyl-1H-indazole-3-yl)-N '-phenylurea;
Its tautomer and pharmacologically acceptable salt thereof.
The present invention also relates to comprise the pharmaceutical composition of formula (I) derivative as active effective constituent, wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1, C (=NH) R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, heterocycle, formyl radical, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5, R6 and R7 are independently from each other following groups: halogen, CN, NO
2, NH
2, OH, COOH, C (O) OR8 ,-O-C (O) R8, NR8R9, NHC (O) R8, C (O) NR8R9, NHC (S) R8, C (S) NR8R9, SR8, S (O) R8, SO
2R8, NHSO
2R8, SO
2NR8R9 ,-O-SO
2R8 ,-SO
2-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C) alkyl, (1-6C) alkoxyl group, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl group, adamantyl or multi-ring alkyl; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
R1, R2, R8, R9, R10 and R11 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group, heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, trifluoromethyl, trifluoromethoxy;
R1 and R2 or R8 and R9 or R10 and R11 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
And when R3 was 6-membered nitrogen-containing heteroaryl base or thiazolyl or imidazolyl Huo oxazolyl, at least one was an aryl unsubstituted or that replaced by one or more substituting groups in R5 and the R6 base, and described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
The invention particularly relates to and comprise the pharmaceutical composition of formula (I) derivative as active effective constituent, wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1, C (=NH) R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, heterocycle, formyl radical, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5 and R6 are independently from each other following groups: halogen, CN, NO
2, NH
2, OH, COOH, C (O) OR8 ,-O-C (O) R8, NR8R9, NHC (O) R8, C (O) NR8R9, NHC (S) R8, C (S) NR8R9, SR8, S (O) R8, SO
2R8, NHSO
2R8, SO
2NR8R9 ,-O-SO
2R8 ,-SO
2-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C) alkyl, (1-6C) alkoxyl group, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl group, adamantyl, multi-ring alkyl; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
R7 is halogen, methyl, cyclopropyl, CN, OH, methoxyl group, trifluoromethyl, vinyl, ethynyl, trifluoromethoxy, NO
2, NH
2Or NMe
2
R1, R2, R8, R9, R10 and R11 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, trifluoromethyl or trifluoromethoxy;
R1 and R2 or R8 and R9 or R10 and R11 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
And when R3 was 6-membered nitrogen-containing heteroaryl base or thiazolyl, imidazolyl Huo oxazolyl, at least one was unsubstituted or by the aryl of one or more replacements and replacement, described substituting group is selected from halogen, CN, NO in R5 and the R6 base
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy and (1-6C) alkyl;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
The present invention preferably relates to and comprises the pharmaceutical composition of formula (I) derivative as active effective constituent, wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, formyl radical, oxo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5 is an aryl;
R6 and R7 are halogen, methyl, cyclopropyl, CN, OH, methoxyl group, trifluoromethyl, vinyl, ethynyl, trifluoromethoxy, NO independently of one another
2, NH
2Or NMe
2
R1 and R2 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, trifluoromethyl or trifluoromethoxy;
R1 and R2 can form 5-or the 6-unit ring that does not contain or contain heteroatoms such as O, S or N;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
The present invention also relates to the purposes of formula (I) Aminoindazole derivatives as medicine, wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1, C (=NH) R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, heterocycle, formyl radical, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5, R6 and R7 are independently from each other following groups: halogen, CN, NO
2, NH
2, OH, COOH, C (O) OR8 ,-O-C (O) R8, NR8R9, NHC (O) R8, C (O) NR8R9, NHC (S) R8, C (S) NR8R9, SR8, S (O) R8, SO
2R8, NHSO
2R8, SO
2NR8R9 ,-O-SO
2R8 ,-SO
2-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C) alkyl, (1-6C) alkoxyl group, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl group, adamantyl or multi-ring alkyl; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
R1, R2, R8, R9, R10 and R11 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group, heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, trifluoromethyl, trifluoromethoxy;
R1 and R2 or R8 and R9 or R10 and R11 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
And when R3 was 6-membered nitrogen-containing heteroaryl base or thiazolyl or imidazolyl Huo oxazolyl, at least one was an aryl unsubstituted or that replaced by one or more substituting groups in R5 and the R6 base, and described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
The invention particularly relates to the purposes of formula (I) Aminoindazole derivatives as medicine, wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1, C (=NH) R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, heterocycle, formyl radical, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5 and R6 are independently from each other following groups: halogen, CN, NO
2, NH
2, OH, COOH, C (O) OR8 ,-O-C (O) R8, NR8R9, NHC (O) R8, C (O) NR8R9, NHC (S) R8, C (S) NR8R9, SR8, S (O) R8, SO
2R8, NHSO
2R8, SO
2NR8R9 ,-O-SO
2R8 ,-SO
2-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C) alkyl, (1-6C) alkoxyl group, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl group, adamantyl, multi-ring alkyl; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
R7 is halogen, methyl, cyclopropyl, CN, OH, methoxyl group, trifluoromethyl, vinyl, ethynyl, trifluoromethoxy, NO
2, NH
2Or NMe
2
R1, R2, R8, R9, R10 and R11 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, trifluoromethyl or trifluoromethoxy;
R1 and R2 or R8 and R9 or R10 and R11 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
And when R3 was 6-membered nitrogen-containing heteroaryl base or thiazolyl or imidazolyl Huo oxazolyl, at least one was an aryl unsubstituted or that replaced by one or more substituting groups in R5 and the R6 base, and described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
The present invention preferably relates to the purposes of formula (I) Aminoindazole derivatives as medicine, wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, formyl radical, oxo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5 is an aryl;
R6 and R7 are halogen, methyl, cyclopropyl, CN, OH, methoxyl group, trifluoromethyl, vinyl, ethynyl, trifluoromethoxy, NO independently of one another
2, NH
2Or NMe
2
R1 and R2 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy;
R1 and R2 can form 5-or the 6-unit ring that does not contain or contain heteroatoms such as O, S or N;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
Particularly, the present invention discloses following content:
Item 1: formula (I) compound:
Wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1, C (=NH) R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, heterocycle, formyl radical, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5, R6 and R7 are independently from each other following groups: halogen, CN, NO2, NH
2, OH, COOH, C (O) OR8 ,-O-C (O) R8, NR8R9, NHC (O) R8, C (O) NR8R9, NHC (S) R8, C (S) NR8R9, SR8, S (O) R8, SO
2R8, NHSO
2R8, SO
2NR8R9 ,-O-SO
2R8 ,-SO
2-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C) alkyl, (1-6C) alkoxyl group, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl group, adamantyl or multi-ring alkyl; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
R1, R2, R8, R9, R10 and R11 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group, heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, trifluoromethyl, trifluoromethoxy;
R1 and R2 or R8 and R9 or R10 and R11 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
And when R3 was 6-membered nitrogen-containing heteroaryl base or thiazolyl or imidazolyl Huo oxazolyl, at least one was an aryl unsubstituted or that replaced by one or more substituting groups in R5 and the R6 base, and described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
Item 2: formula (I) compound:
Wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1, C (=NH) R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, heterocycle, formyl radical, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5 and R6 are independently from each other following groups: halogen, CN, NO
2, NH
2, OH, COOH, C (O) OR8 ,-O-C (O) R8, NR8R9, NHC (O) R8, C (O) NR8R9, NHC (S) R8, C (S) NR8R9, SR8, S (O) R8, SO
2R8, NHSO
2R8, SO
2NR8R9 ,-O-SO
2R8 ,-SO
2-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C) alkyl, (1-6C) alkoxyl group, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl group, adamantyl, multi-ring alkyl; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
R7 is halogen, methyl, cyclopropyl, CN, OH, methoxyl group, trifluoromethyl, vinyl, ethynyl, trifluoromethoxy, NO
2, NH
2Or NMe
2
R1, R2, R8, R9, R10 and R11 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, trifluoromethyl or trifluoromethoxy;
R1 and R2 or R8 and R9 or R10 and R11 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
And when R3 was 6-membered nitrogen-containing heteroaryl base or thiazolyl or imidazolyl Huo oxazolyl, at least one was an aryl unsubstituted or that replaced by one or more substituting groups in R5 and the R6 base, and described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
Item 3: formula (I) compound:
Wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, formyl radical, oxo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5 is an aryl;
R6 and R7 are halogen, methyl, cyclopropyl, CN, OH, methoxyl group, trifluoromethyl, vinyl, ethynyl, trifluoromethoxy, NO independently of one another
2, NH
2Or NMe
2
R1 and R2 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy;
R1 and R2 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
Item 4: 1 compound is selected from:
N-(two the ring [2.2.1] heptan-5-alkene-2-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3, the 3-dimethylbutyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3-phenyl propyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(cyclopropyl methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(cyclopentyl-methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-(methylthio group) propyl group]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(phenylethyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(cyclohexyl methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-propyl group-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(2,2,3,3,4,4,4-seven fluorine butyl)-5-phenyl-1H-indazole-3-amine hydrate;
6-chloro-7-fluoro-N-(4,4,4-trifluoro butyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(4-p-methoxy-phenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(phenyl methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(4-cyano-phenyl) methyl]-5-phenyl-1H-indazole-3-amine;
The N-[(4-chloro-phenyl-) methyl]-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(3-p-methoxy-phenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[4-(trifluoromethoxy) phenyl] methyl]-5-phenyl-1H-indazole-3-amine;
N-[4-[[[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] amino] methyl] phenyl] ethanamide;
6-chloro-7-fluoro-N-[(3, the 5-dichlorophenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[4-(trifluoromethyl) phenyl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(4-fluorophenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-(4-methylphenoxy) phenyl methyl]-5-phenyl-1H-indazole-3-amine;
N-(2,2,3,3,4,4,4-seven fluorine butyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[3, two (trifluoromethyl) phenyl of 5-] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[3-(trifluoromethyl) phenyl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(6-methoxyl group-2-naphthyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(pentafluorophenyl group) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[4-(methylthio group) phenyl] methyl]-5-phenyl-1H-indazole-3-amine;
N-[(4-chloro-3-fluorophenyl) methyl]-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(3,3, the 3-trifluoro propyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(3-thienyl methyl)-1H-indazole-3-amine;
N-(two the ring [2.2.1] heptan-5-alkene-2-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
N-(1,1 '-xenyl-4-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[4-(dimethylamino) phenyl] methyl]-5-phenyl-1H-indazole-3-amine;
N-(2,2 '-bithiophene-5-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[1-(phenyl methyl)-1H-imidazoles-2-yl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[1-methyl isophthalic acid H-imidazoles-2-yl] methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(1-Methyl-1H-indole-3-yl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(5-methyl-2-furyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(1H-pyrroles-2-ylmethyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[(1H-imidazoles-2-yl) methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[(1H-imidazol-4 yl) methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(1H-pyrazole-3-yl methyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[2-methyl isophthalic acid H-imidazol-4 yl] methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(3,5-dimethyl-1-phenyl-1H-pyrazoles-4-yl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[2-phenyl-1H-imidazol-4 yl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[5-(4-chloro-phenyl-)-2-furyl] methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[(1-methyl isophthalic acid H-pyrroles-2-yl) methyl]-1H-indazole-3-amine;
4-[5-[[[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] amino] methyl]-the 2-furyl]-benzsulfamide;
6-chloro-7-fluoro-5-phenyl-N-(3-thienyl methyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[2-phenyl-1H-imidazol-4 yl] methyl]-1H-indazole-3-amine;
2-[[[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] amino] methyl]-5-(methylthio group)-1H-imidazoles-4-ethyl formate;
6-chloro-7-fluoro-5-phenyl-N-[[5-[4-(trifluoromethyl) phenyl]-the 2-furyl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[2-(piperidino) ethyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[2-(4-morpholinyl) ethyl]-5-phenyl-1H-indazole-3-amine;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(3, the 5-dichlorophenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(2-propenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(phenyl methyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-Phenoxyphenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-p-methoxy-phenyl) methyl] urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-[4-(trifluoromethyl) phenyl] urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-p-methoxy-phenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-cyclohexyl urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-propyl group urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-chloro-phenyl-) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-fluorophenyl) urea;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-N '-(three ring [3.3.1.1
3,7] last of the ten Heavenly stems)-1-base urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-aminomethyl phenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-methyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-cyano group-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-cyclopropyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-hydroxyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-methoxyl group-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-trifluoromethyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-trifluoromethoxy-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-nitro-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-amino-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-dimethylamino-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-ethynyl-5-phenyl-1H-indazole-3-yl) urea;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-methyl-benzsulfamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] Toluidrin;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-2-third sulphonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-2,2,2-trifluoro ethyl sulfonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-the 2-thiophenesulfonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] benzsulfamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-(trifluoromethyl) benzsulfamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-5-(3-isoxazolyl)-2-thiophenesulfonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-fluorobenzene sulphonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-the 4-methoxybenzenesulphoismide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] the benzene Toluidrin;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-1-methyl isophthalic acid H-imidazoles-4-sulphonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-(1, the 1-dimethyl ethyl) benzsulfamide;
N-[4-[[(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl) amino] alkylsulfonyl] phenyl] ethanamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-methylbenzene Toluidrin;
6-chloro-7-fluoro-N-(pentafluorophenyl group)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3, the 4-difluorophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(2,3,5,6-tetrafluoro phenyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(2,4, the 6-trifluorophenyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(4-fluorophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-(trifluoromethyl) phenyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[4-(trifluoromethyl) phenyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-fluoro-5-(trifluoromethyl) phenyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(4-nitrophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3-nitrophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3-p-methoxy-phenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(4-p-methoxy-phenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N, 5-phenylbenzene-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(1-pyridyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(2-pyridyl)-5-phenyl-1H-indazole-3-amine;
N-butyl-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-phenylurea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-3-methoxybenzenesulphoismide;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
Item 5: the compound in the item 1 or 2 is selected from:
Piperidines-1-formic acid (6,7-two fluoro-5-phenyl-1H-indazole-3-yl) acid amides;
Tetramethyleneimine-1-formic acid (6,7-two fluoro-5-phenyl-1H-indazole-3-yl) acid amides;
1-(6,7-two fluoro-5-phenyl-1H-indazole-3-yl)-3-[3-(4-methylpiperazine-1-yl) propyl group] urea;
Its tautomer and pharmacologically acceptable salt thereof.
6: each the compound of item 1-5 that is used for preparing medicine.
7: pharmaceutical composition, this pharmaceutical composition contain among the 1-5 each compound in pharmaceutically acceptable medium.
8: 7 medicine, this medicine contain among at least a the 1-5 each compound, are used for the treatment of the disease that relates to the Protein tau phosphorylation.
Item 9: the medicine of item 6, this medicine contains among at least a the 1-5 each compound, is used for the treatment of neurodegenerative disease, apoplexy, cranium and trauma of spinal cord and peripheral neuropathy, obesity, metabolic disease, type ii diabetes, essential hypertension, atherosclerotic cardiovascular disease, polycystic ovary syndrome, X syndrome, immune deficiency and cancer.
Item 10: the medicine of item 9, described neurodegenerative disease is Alzheimer, Parkinson's disease, os frontoparietale dementia, corticobasal degeneration or Pick's disease.
Item 11: the method for preparation 1 defined formula (I) compound, wherein in formula (I), R3 is (1-6C) alkyl, aryl (1-6C) alkyl, heteroaryl (1-6C) alkyl, Heterocyclylalkyl, cycloalkyl or multi-ring alkyl, these groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, formyl radical, oxo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl and R1, R2 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another; they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy; Described method is included in the methylene dichloride, be that formula (I) derivative, R1CHO derivative and the sodium triacetoxy borohydride of H is prepared with R3 wherein, and resulting product does not transform or be converted into pharmacologically acceptable salt.
Item 12: the method for preparation 1 defined formula (I) compound, wherein in formula (I), R3 is that CONR1R2 or CSNR1R2 and R1 and R2 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy; Described method is included in the tetrahydrofuran (THF), adopt OCNR1 and wherein R3 be that formula (I) derivative of H is prepared, and resulting product does not transform or is converted into pharmacologically acceptable salt.
Item 13: the method for preparation 1 defined formula (I) compound, wherein in formula (I), R3 is SO
2R1 and R1 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl, and they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy; Described method is included in alkali and exists down, in methylene dichloride, uses SULPHURYL CHLORIDE R1SO
2Cl and wherein R3 be that formula (I) derivative of H is prepared, and resulting compound does not transform or is converted into pharmacologically acceptable salt.
Item 14: midbody product, for:
6,7-two fluoro-1H-indazole-3-amine;
N-(6,7-two fluoro-1H-indazole-3-yls) butyramide:
N-[6,7-two fluoro-1-[[2-(three silyls) oxyethyl group] methyl]-1H-indazole-3-yl] butyramide;
N-[5-bromo-6,7-two fluoro-1-[[2-(three silyls) oxyethyl group] methyl]-1H-indazole-3-yl]-butyramide;
N-[6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-yl] butyramide;
6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-amine;
6,7-two fluoro-5-phenyl-1H-indazole-3-amine.Formula (I) derivative can be obtained by corresponding 3-aminoderivative (V), and wherein, 1-position nitrogen is unprotected or by group Pr protection.Pr be three silyl ethoxyl methyls, tosyl group, methylsulfonyl or benzyl or as T.W.Greene in " protecting group in the organic synthesis ", the group of pointing out among the J.Wiley-Interscience Publication (1999) that becomes known for protecting NH base in the aromatic heterocycle;
The amino 1H-indazole of formula (II) 3-can be according to R.F.Kaltenbach at Bioorg.Med.Chem.Lett.,
9(15), method described in the 2259-62 (1999), by with 2-fluorine benzonitrile and hydrazine hydrate or hydrochloride at ethanol or just-obtained in back flow reaction 2-18 hour in the butanols.
Compound, wherein R5 and R6 are independently from each other following groups: halogen, CN, NO
2, NH
2, OH, COOH, C (O) OR8 ,-O-C (O) R8, NR8R9, NHC (O) R8, C (O) NR8R9, NHC (S) R8, C (S) NR8R9, SR8, S (O) R8, SO
2R8, NHSO
2R8, SO
2NR8R9 ,-O-SO
2R8 ,-SO
2-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C) alkyl, (1-6C) alkoxyl group, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, cycloalkyl, alkenyl, alkynyl group or adamantyl; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, oxo, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl; Can by relate to the chemical reaction of palladium: Suzuki (A.Suzuki, Pure Appl.Chem.,
63,419-22 (1991), Stille (J.Stille, Angew.Chem., Int.Ed.,
25, 508-24 (1986)), Heck (R.F.Heck, Org.React.,
27, 345-90 (1982)), Sonogashira, (K.Sonogashira, Synthesis, 777 (1977)), Buckwald (S.L.Buckwald, Acc.Chem.Re.,
31, 805 (1998)), obtain by corresponding halide derivative.
For this reason, be necessary protective reaction functional group.Therefore, OH, SH, COOH and NH
2Functional group must protect before carrying out coupling.Protecting group is according to well known by persons skilled in the art, and particularly T.W.Greene is in " protecting group in the organic synthesis ", and any method of describing among the J.Wiley-IntersciencePublication (1999) is introduced.Preferably with group such as tert-butoxycarbonyl or silicon derivative protection 1-position nitrogen.Preferably with tert-butyl dimethyl silanyl or three silyldisilanyls that can remove by fluoride anion or acetate, particularly with can be by the tetrabutylammonium (J.P.Whitten that in solvent such as tetrahydrofuran (THF) Huo diox, refluxes, J.Org.Chem., 51,1891 (1986); B.H.Lipshutz, Tetrahedron Lett., 4095 (1986)) or undertaken by in methyl alcohol or ethanol, reflux three silyl ethoxyl methyls of fracture of 2N hydrochloric acid.
The 1-position can be by initial compounds and three silyl ethoxymethyl chloride at room temperature with the derivative of three silyl ethoxyl methyls protections, in the presence of sodium hydride, reaction obtains (J.P.Whitten, J.Org.Chem. in solvent such as dimethyl formamide, 51,1891 (1986); M.P.Edwards, Tetrahedron, 42,3723 (1986)).
Similarly, the 1-NH nitrogen functional group of indazole will protect with group such as silyl derivative, benzyl, carbamate or tosyl group.For example, be coupled on the halogenated derivative in 6-position with palladium if desired, be necessary protection 1-as described below position nitrogen (X=Cl, Br or I):
Deprotection can be according to well known by persons skilled in the art and T.W.Greene in " protecting group in the organic synthesis ", and the method for describing among the J.Wiley-Interscience Publication (1999) is carried out.For example, if 1-position protecting group is three silyl ethoxyl methyls, it can be as described below by reacting deprotection with tetrabutylammonium so:
One in using the palladium chemical coupling in related R5 or the R6 base contains reactive functional groups, as hydroxyl, amine, mercaptan or carboxylic acid or when comprising heteroatoms usually, also is necessary carrying out protecting the latter before the coupling with palladium.Therefore, for example, phenol functional group will be introduced protection form (for example O-benzyl) by chlorinated derivatives, protect 1-position nitrogen as previously described:
Remove benzyl subsequently, for example undertaken by three silyl iodide reflow treatment in acetonitrile.Also can protect with three silyl ethoxyl methyls, described protecting group can be by tetrabutylammonium reflux in solvent such as tetrahydrofuran (THF) or diox (J.P.Whitten, J.Org.Chem., 51,1891 (1986); B.H.Lipshutz, Tetrahedron Lett., 4095 (1986)) or by the fracture that in methyl alcohol or ethanol, refluxes of 2N hydrochloric acid.
When R5 and R6 were aryl and halogen independently of one another, aryl functional group introduced by be coupled to the bromination position with palladium, and 1-and 3-position nitrogen are suitably protected.Preferably, Pr represent three silyl ethoxyl methyls and Pr ' expression just forming with nitrogen-butyl amide just-the butyl carbonyl.The acid amides deprotection steps refluxes in DMF and carries out in a week by in the presence of thanomin.This fracture also can be carried out (R J Griffin with tin protochloride in ethanol, J.Chem.Soc.Perkin I, 1992,1811-1819) or also can in methyl alcohol, carry out (Y.Furukawa with sodium methylate, Chem.Pharm.Bull., 1968,16,1076) or with any other alcoholate in corresponding alcohol, carry out.
When R5 and R6 were aryl and halogen independently of one another, aryl functional group introduced by be coupled to the bromination position with palladium, and 1-and 3-position nitrogen are suitably protected.Preferably, Pr represent three silyl ethoxyl methyls and Pr ' expression just forming with nitrogen-butyl amide just-the butyl carboxyl.For example electrophilic substitution is with nitronium tetrafluoroborate (NO
2BF
4) carry out.The coupling of 5-position utilizes the palladium chemistry to carry out (Suzuki, Heck or Sonogashira coupling).Introduce bromine or introduce aryl, heteroaryl, alkyl, alkenyl, alkynyl group or ethynyl by reduction, halogenation, the 7-bit function is turned to have required substituent function by palladium chemical coupling (Suzuki, Heck or Sonogashira coupling).The acid amides deprotection steps refluxes in DMF and carries out in a week by in the presence of thanomin.This fracture also can be carried out (R J Griffin with tin protochloride in ethanol, J.Chem.Soc.Perkin I, 1992,1811-1819) or also can in methyl alcohol, carry out (Y.Furukawa with sodium methylate, Chem.Pharm.Bull., 1968,16,1076) or with any other alcoholate in corresponding alcohol, carry out.3-position deprotection produces NH
2Functional group, the radical reaction that it can be as described below and essential is introduced the 3-position with needed substituting group.
Formula (II) compound be preparation by the primary amine functional group of 3-Aminoindazole at all popular responses of this functional group, as: alkylation, acidylate, react reduction then, sulfonation with carbonyl derivative, be converted into urea or carbamate, arylation (Castro reaction or Buchwald reaction) wait in the initiator of various products of acquisition.
General formula (I) derivative, wherein R3 is H, when Pr is three silyl ethoxyl methyls, its reductive amination can be in " organic reaction ", 59 volumes, 1-714 (E.Baxter, A.Reitz) under the condition of describing in, in the presence of R1CHO type aldehyde, in methylene dichloride, utilize boron derivative such as sodium triacetoxy borohydride to carry out, or undertaken by other reductive agent that is generally used for reducing imines, form product, wherein R3 is (1-6C) alkyl, aryl (1-6C) alkyl, heteroaryl (1-6C) alkyl, Heterocyclylalkyl, cycloalkyl or multi-ring alkyl, these groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, formyl radical, oxo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl.
General formula (I) derivative, wherein R3 is H, with the condensation of OCNR1 type isocyanic ester especially can be in tetrahydrofuran (THF) and according to Comprehensive Organic Functional GroupTransformations, Vol.6 (Katritzky, Meth-Cohn, Rees 1995) in the embodiment that describes carry out, form product, wherein R3 is CONR1R2 or CSNR1R2, R1 and R2 are hydrogen independently of one another, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy.
General formula (I) derivative, wherein R3 is H, its sulfonation can exist down at alkali (tertiary amine particularly is as triethylamine, or aromatic amine, as pyridine), uses R1SO in conventional solvent such as methylene dichloride
2C1 type SULPHURYL CHLORIDE is carried out, and forms product, and wherein R3 is SO
2R1 and R1 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl, and they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy.
Separate type (I) compound and can for example carry out purifying by common known method by crystallization, chromatography or extraction.
Formula (I) compound can not transform or utilize inorganic or organic acid and by described acid at organic solvent, be converted into additive salt as the effect in alcohol, ketone, ether or the chlorinated solvent.These salt also constitute part of the present invention.
The example of pharmacologically acceptable salt can be mentioned following salt: benzene sulfonate, hydrobromate, hydrochloride, Citrate trianion, esilate, fumarate, gluconate, iodate, maleate, isethionate, mesylate, methylene radical two-β-chomene formate, nitrate, oxalate, embonate, phosphoric acid salt, salicylate, succinate, vitriol, tartrate, cariamyl and right-tosylate.
Formula (I) compound is kinase inhibitor and therefore is used for prevention and treatment neurodegenerative disease, Alzheimer, Parkinson's disease, os frontoparietale dementia, corticobasal degeneration, Pick's disease, apoplexy, cranium and trauma of spinal cord and peripheral neuropathy, obesity, essential hypertension, atherosclerotic cardiovascular disease, polycystic ovary syndrome, X syndrome, immune deficiency and cancer.
Determine active by measuring to the inhibition of Protein tau phosphorylation in the section of adult rats pallium.
With 8-10 week macrandry OFA rat (Iffa-Credo) the preparation thickness of putting to death by detruncation is the pallium section of 300 μ m.They contain in the DMEM substratum of pyruvate salt and glucose 4.5g/l at 5ml, hatch under 37 ℃ 40 minutes.This substratum washed twice is used in this section subsequently, is divided in the microtubule (containing or do not contain packing 50 μ l in the substratum of test compound at 500 μ l) and hatches under 37 ℃ of stirrings.After two hours, by centrifugal termination test.Section is dissolved, ultrasonic and under 4 ℃, under 18300g centrifugal 15 minutes.(BCA Protein Assay Pierce) measures proteinic concentration by the commercial measuring method based on the Lowry method in the supernatant liquor.
In 4-12%Bis-tris setting type gel, separating also electromigration in the presence of the MOPS-SDS buffer reagent to the Nitrocellulose film at 10 minutes sample of 70 ℃ of following sex change in advance.Carry out with monoclonal antibody AD2 immune labeled, the Ser396/404 phosphorylation epitope of described monoclonal antibody specific recognition Protein tau.By add second kind of anti-mouse IgGs and with peroxidase link coupled antibody and chemoluminescence substrate development immune-reactive protein.(GeneGnome, ' GeneTools ' software Ozyme) come finally the radioactive automatic developing figure that is obtained to be carried out quantitatively so that measure IC to utilize Syngene
50Value.
Formula (I) compound exhibits is very advantageously active, especially the IC of some compound
50Value is less than 100 μ M.
The following example is illustrative rather than definitive thereof the present invention.
In the condition by the LC/MS assay products, the LC part is provided by Waters Alliance 2695 devices, and the mass spectrum part is provided by Waters-Micromass Platform II.
The preparation of midbody product:
6,7-two fluoro-1H-indazole-3-amine:
0.32cm
3The hydrazine monohydrate is added to 0.46cm
32,3, the 10cm of 4-trifluoro benzonitrile
3In the ethanol solution.This medium was heated 17 hours down at about 75 ℃, add 10cm then
3Ethyl acetate, 5cm
3Tetrahydrofuran (THF) and 5cm
3Distilled water.The phase post precipitation separates organic phase and uses 10cm
3Distilled water wash is used 10cm then
3The saturated sodium-chloride water solution washing.The phase post precipitation separates organic phase, uses dried over mgso, filters and decompression (2kPa; 50 ℃) be concentrated into dried.Residue is by under the 50kPa Ar Pressure, at silicagel column (granularity 40-60 μ m; Diameter 1.5cm) goes up the chromatogram chromatography purification, with cyclohexane/ethyl acetate mixture (50/50 volume ratio) wash-out.Merge to contain and expect the cut of product, (2kPa then reduces pressure; 40 ℃) evaporation; Dry (90Pa; 40 ℃) after, 100mg 6 obtained, the white solid of 7-two fluoro-1H-indazole-3-amine, 183 ℃ of fusing points.
1H NMR composes (300MHz, (CD
3)
2SO d6, δ represents with ppm): 5.57 (complicated peaks: 2H); 6.93 (mt:1H); (7.52 ddd, J=8.5-4.5 and 1Hz:1H); 12.01 (complicated peak: 1H).
N-(6,7-two fluoro-1H-indazole-3-yls) butyramide:
With 0.61cm
3It is above-mentioned 6 that butyryl chloride is added to 1g, the 15cm of 7-two fluoro-1H-indazole-3-amine
3In the pyridine solution, be cooled to about 3 ℃ after, mixture was at room temperature placed 76 hours.With reaction medium decompression (2kPa; 40 ℃) concentrate, residue is dissolved in 25cm
3Ethyl acetate and 25cm
3In the water.Organic phase 25cm
3Distilled water wash is used 25cm then
3The saturated sodium-chloride water solution washing.After dried over mgso, filter and decompression (2kPa; 40 ℃) concentrate, residue is by under the 50kPa Ar Pressure, at silicagel column (granularity 40-60 μ m; Diameter 3cm) goes up the chromatogram chromatography purification, with methylene chloride/methanol mixture (98/2 volume ratio) wash-out.Merge to contain and expect the cut of product, (2kPa then reduces pressure; 40 ℃) evaporation; Dry (90Pa; 40 ℃) after, the white solid of 596mg N-(6,7-two fluoro-1H-indazole-3-yls) butyramide, 191 ℃ of fusing points obtained.
1H NMR composes (300MHz, (CD
3)
2SO d6, δ represents with ppm): 0.97 (t, J=7.5Hz:3H); 1.67 (mt:2H); 2.40 (t, J=7Hz:2H); 7.10 (mt:1H); (7.63 wide dd, J=9 and 4.5Hz:1H); 10.47 (the peak of wide complexity: 1H); 13.35 (the peak of wide complexity: 1H).
N-[6,7-two fluoro-1-[[2-(three silyls) oxyethyl group] methyl]-1H-indazole-3-yl] butyramide
180cm with 1.1g N-(6, the 7-two fluoro-1H-indazole-3-yls) butyramide of above-mentioned preparation
3Dimethyl formamide solution was added drop-wise to the 50cm of 1.65g sodium hydride 60% oily matter through 3 hours
3In the dimethyl formamide solution.Reaction medium is evaporated to dry doubling is dissolved in 250cm
3Ethyl acetate and 200cm
3In the water; The phase post precipitation divides organic phase, uses 150cm
3Dried over mgso is used in water washing, filters and decompression (2kPa; 50 ℃) be concentrated into dried.Crude product is by under the 50kPa Ar Pressure, at silicagel column (granularity 40-60 μ m; Diameter 6cm) goes up the chromatogram chromatography purification, with cyclohexane/ethyl acetate mixture (80/20 volume ratio) wash-out.Merge to contain and expect the cut of product and the (2kPa that reduces pressure; 50 ℃) evaporation, obtain 7.3g N-[6,7-two fluoro-1-[[2-(three silyls) oxyethyl group] methyl]-1H-indazole-3-yl] yellow oil of butyramide.
1H NMR composes (300MHz, (CD
3)
2SO d6, δ represents with ppm) :-0.09 (s:9H); 0.82 (t, J=8Hz:2H); 0.96 (t, J=7.5Hz:3H); 1.67 (mt:2H); 2.41 (t, J=7Hz:2H); 3.56 (t, J=8Hz:2H); 5.66 (s:2H); (7.22 ddd, J=11-9 and 7Hz:1H); (7.69 wide dd, J=9 and 4.5Hz:1H); 10.60 (complicated peak: 1H).
Mass spectrum: M=369;
N-[5-bromo-6,7-two fluoro-1-[[2-(three silyls) oxyethyl group] methyl]-1H-indazole-3-yl]-
Butyramide
With 0.87cm
3Pyridine is added to the above-mentioned N-[6 of 1g, 7-two fluoro-1-[[2-(three silyls) oxyethyl group] methyl]-1H-indazole-3-yl] 30cm of butyramide
3In the chloroformic solution, add 0.56cm then
3Bromine, mixture reflux and spend the night.With 50cm
3Methylene dichloride and 50cm
310% sodium thiosulfate solution is added in this reaction medium.Stir after 10 minutes, by removing by filter insoluble substance with sinter funnel, organic phase 50cm
3Water and 50cm
3The saturated nacl aqueous solution washing.The phase post precipitation separates organic phase, with dried over mgso, filtration and decompression (2kPa; 45 ℃) be concentrated into dried.1.1g crude product is by under the 50kPa Ar Pressure, at silicagel column (granularity 40-60 μ m; Diameter 3cm) goes up the chromatogram chromatography purification, with cyclohexane/ethyl acetate mixture (90/10 volume ratio) wash-out.Merge to contain and expect the cut of product and the (2kPa that reduces pressure; 50 ℃) evaporation.Dry (90Pa; 45 ℃) after, obtain 230mg N-[5-bromo-6,7-two fluoro-1-[[2-(three silyls) oxyethyl group] methyl]-1H-indazole-3-yl] colorless oil of butyramide.
1H NMR composes (300MHz, (CD
3)
2SO d6, δ represents with ppm) :-0.08 (s:9H); 0.82 (t, J=8Hz:2H); 0.96 (t, J=7.5Hz:3H); 1.67 (mt:2H); 2.42 (t, J=7Hz:2H); 3.55 (t, J=8Hz:2H); 5.66 (s:2H); (8.08 dd, J=6 and 2Hz:1H); 10.72 (complicated peak: 1H).
Mass spectrum: M=447;
N-[6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-
Base] butyramide
30cm with 469mg phenyl-boron dihydroxide, 760mg yellow soda ash
3The aqueous solution and 379mg tetrakis triphenylphosphine palladium are added to the N-[5-bromo-6 of the above-mentioned preparation of 1.15g, 7-two fluoro-1-[[2-(three silyls) oxyethyl group] methyl]-1H-indazole-3-yl] 150cm of butyramide
3In the dioxane solution, this mixture was refluxed 4 hours.Reaction medium 100cm
3Ethyl acetate and 75cm
3Water dilutes and filters by the sinter funnel of filling Celite.The phase post precipitation separates organic phase, with washing 75cm
3Water and 75cm
3Dried over mgso is used in the saturated nacl aqueous solution washing, filters and decompression (2kPa; 50 ℃) be concentrated into driedly, obtain the dark oil thing of 2g crude product.Crude product is by under the 50kPa Ar Pressure, at silicagel column (granularity 40-60 μ m; Diameter 3.5cm) goes up the chromatogram chromatography purification, with cyclohexane/ethyl acetate mixture (85/15 volume ratio) wash-out.Merge to contain and expect the cut of product, (2kPa reduces pressure; 50 ℃) evaporation and dry (90Pa, 45 ℃), obtain 1.1g N-[6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-yl] yellow oil of butyramide.
1H NMR composes (300MHz, (CD
3)
2SO d6, δ represents with ppm) :-0.05 (s:9H); 0.84 (t, J=8Hz:2H); 0.95 (t, J=7.5Hz:3H); 1.66 (mt:2H); 2.43 (t, J=7Hz:2H); 3.59 (t, J=8Hz:2H); 5.69 (s:2H); 7.40-7.65 (mt:5H); 7.82 (wide d, J=7Hz:1H); 10.64 (complicated peak: 1H).
Mass spectrum: M=445;
N-[6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-amine
With 1.1cm
3Thanomin and 1.50g salt of wormwood successively are added to the above-mentioned N-[6 of 1.6g, 7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-yl] 50cm of butyramide
3In the dimethyl formamide solution, mixture is refluxed a week.Reaction medium is evaporated to dry doubling and is dissolved in 150cm
3Ethyl acetate and 75cm
3In the water.The phase post precipitation separates organic phase and uses 75cm in succession
3* 2 water and 50cm
3The salt water washing.The organic phase dried over mgso is filtered and decompression (2kPa; 50 ℃) be concentrated into dried.Resulting crude product oily matter is by under the 50kPa Ar Pressure, at silicagel column (granularity 40-60 μ m; Diameter 4cm) goes up the chromatogram chromatography purification, with cyclohexane/ethyl acetate mixture (80/20 volume ratio) wash-out.Merge to contain and expect the cut of product and the (2kPa that reduces pressure; 50 ℃) evaporation.Dry (90Pa; 45 ℃) after, obtain 0.32g 6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-amine.
6,7-two fluoro-5-phenyl-1H-indazole-3-amine:
1.1ml 2N HCl is added to 661mg 6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-the 15ml methanol solution of 1H-indazole-3-amine in.This is reflected at 140 ℃ of microwaves and carried out 3 minutes.Use saturated KH
2PO
4Solution hydrolysis and with behind the dichloromethane extraction, evaporating solvent, residue be chromatography (dichloromethane/ethyl acetate) on silica gel, obtains 314mg 6,7-two fluoro-5-phenyl-1H-indazole-3-amine.
Embodiment 1:Piperidines-1-formic acid (6,7-two fluoro-5-phenyl-1H-indazole-3-yl)-acid amides
Step 1
131 μ l pyridines and 154 μ l Vinyl chloroformates be added in succession 387.8mg (6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-the 8ml dichloromethane solution of 1H-indazole-3-amine compound in.After 75 minutes, reaction finishes.Extract after the hydrolysis and evaporation, obtain 840mg (6,7-two fluoro-5-phenyl-1H-indazole-3-yl) urethanum crude product.
Step 2
The 184mg piperidines is added in the 2.5ml phenylfluoroform of 161mg (6,7-two fluoro-5-phenyl-1H-indazole-3-yl) urethanum crude product, this is reflected under 200 ℃ of microwaves and carried out 20 minutes.Behind preparation LC/MS (acetonitrile/pH 9 damping fluids) purifying, obtain 80mg piperidines-1-formic acid (6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-yl) acid amides.
Step 3
With 80mg piperidines-1-formic acid (6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-yl) the 2.5ml methanol solution of acid amides is with 0.82ml 2N HCl reflow treatment 1 hour.Evaporation and by behind preparation LC/MS (acetonitrile/pH 9 damping fluids) purifying obtains 11mg piperidines-1-formic acid (6,7-two fluoro-5-phenyl-1H-indazole-3-yl) acid amides.
Mass spectrum: retention time 3.99; 357=[M+H]
+
1H NMR spectrum (300MHz, (DMSO-d6, δ represent with ppm): 1.50 (m, 4H); 1.58 (m, 2H); 3.45 (m, 4H); 7.42 (m, 1H); 7.51 (m, 5H); 9.16 (s, 1H); 13.20 (bs, 1H)
Embodiment 2: tetramethyleneimine-1-formic acid (6,7-two fluoro-5-phenyl-1H-indazole-3-yl)-acid amides
Step 1
The 154mg tetramethyleneimine is added in the 2.5ml phenylfluoroform solution of 161mg (6,7-two fluoro-5-phenyl-1H-indazole-3-yl) urethanum, this is reflected under 200 ℃ of microwaves and carried out 20 minutes.Product is purifying on silicagel column, obtain 75mg tetramethyleneimine-1-formic acid (6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-yl) acid amides.
Step 2
With 75mg tetramethyleneimine-1-formic acid (6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-yl) the 3ml methanol solution of acid amides is with 0.82ml 2N HCl reflow treatment 1 hour.Evaporation and by behind preparation LC/MS (acetonitrile/pH 9 damping fluids) purifying obtains 36mg tetramethyleneimine-1-formic acid (6,7-two fluoro-5-phenyl-1H-indazole-3-yl) acid amides.
Mass spectrum: retention time 3.72 minutes; 343=[M+H]
+
1H NMR spectrum (300MHz, (DMSO-d6, δ represent with ppm): 1.86 (m, 4H); 3.40 (m, 4H); 7.42 (m, 1H); 7.45-7.54 (m, 4H); 7.63 (bd, J=7Hz, 1H); 8.84 (s, 1H); 13.20 (bs, 1H);
Embodiment 3: carry out according to embodiment 2, begin, obtain 1-(6,7-two fluoro-5-phenyl-1H-indazole-3-yl)-3-[3-(4-methylpiperazine-1-yl) propyl group with 3-(4-methylpiperazine-1-yl) propyl group amine] urea.
1H NMR spectrum (300MHz, (DMSO-d6, δ represent with ppm): 1.92 (m, 2H); 2.82 (s, 3H); 3.01-3.75 (m, part is sheltered, 12H); 7.43 (m, 1H); From 7.47-7.56 (m, 4H); 7.71 (t, J=7Hz, 1H); 8.05 (dd, J=1.5-7Hz, 1H); 9.61 (s, 1H);
Mass spectrum: retention time 2.57 minutes; 429=[M+H]
+
Pharmaceutical composition of the present invention comprise pure state or with any other can be formula (I) compound of composition forms of pharmaceutically acceptable product combination of inert or physiologically active or the salt of described compound.Medicine of the present invention can be by oral, parenteral route, rectum or topical.
The solids composition of oral administration can use tablet, pill, pulvis (hard gelatin capsule, cachet) or granule.In these compositions, effective constituent of the present invention under argon gas with one or more inert diluents, mix as starch, Mierocrystalline cellulose, sucrose, lactose or silicon-dioxide.These compositions can also comprise the material except that thinner, and one or more lubricants for example are as Magnesium Stearate or talcum powder, tinting material, Drug coating (drageeing) or glaze.
The liquid composition of oral administration can use and comprise inert diluent, as pharmaceutically acceptable solution, suspension, emulsion, syrup and the elixir of water, ethanol, glycerine, vegetables oil or whiteruss.These compositions can comprise the material except that thinner, for example wetting agent, sweeting agent, thickening material, correctives or stablizer.
The aseptic composite of parenteral administration preferably can be solution, suspension or the emulsion of water or non-water form.Solvent or carrier can make water, propylene glycol, polyoxyethylene glycol, vegetables oil, particularly sweet oil, injectable organic ester, for example ethyl oleate or other suitable organic solvent.These compositions also can comprise adjuvant, particularly wetting agent, isotonic regulator, emulsion, dispersion agent and stablizer.Can be by several modes, for example by sterile filtration, in composition, incorporate sterilant, irradiation or heat sterilization into and sterilize.They also can be prepared into the sterilization solids composition form that can be dissolved in use in sterilization water or any other sterile medium.
The composition of rectal administration is suppository or rectum capsule, and they contain vehicle except that active result, as theobroma oil, semi-synthetic glyceryl ester or polyoxyethylene glycol.
Topical drug delivery composition can be, for example creme, lotion, eye drops, collutory, nasal drop or aerosol.
To be formula (I) Aminoindazole compound and pharmacologically acceptable salt thereof and they be used to prevent and treat the pharmaceutical composition of the disease that abnormal kinase causes in the preparation expection to theme of the present invention, for example, described disease relates to neurodegenerative disease, Alzheimer, Parkinson's disease, the os frontoparietale dementia, corticobasal degeneration, Pick's disease, apoplexy, cranium and trauma of spinal cord and peripheral neuropathy, obesity, metabolic disease, type ii diabetes, essential hypertension, atherosclerotic cardiovascular disease, polycystic ovary syndrome, X syndrome, immune deficiency and cancer.
Abnormal kinase can mention, for example PI3K, AkT or GSK3 'beta ' activity are unusual, CDKs is active unusual etc.
In the mankind's treatment, The compounds of this invention be used in particular for treatment and/prevention neurodegenerative disease, Alzheimer, Parkinson's disease, os frontoparietale dementia, corticobasal degeneration, Pick's disease, apoplexy, cranium and trauma of spinal cord and peripheral neuropathy, obesity, metabolic disease, type ii diabetes, essential hypertension, atherosclerotic cardiovascular disease, polycystic ovary syndrome, X syndrome, immune deficiency and cancer.
Dosage depends on expected results, treatment time length and employed route of administration; Grownup's oral dosage every day is usually at 5mg-1000mg, and unitary dose is the 1mg-250mg active substance.
Usually, the doctor will be that specific factor is determined appropriate dosage for the treatment experimenter according to age, body weight and all.
The following example is used to illustrate composition of the present invention.
Embodiment A
The hard gelatin capsule that contains 50mg active ingredient and following component according to the usual method preparation:
-Shi (I) compound ... ... ... ... ... ... ... ... ... ... ... 50mg
-Mierocrystalline cellulose ... ... ... ... ... ... ... ... ... ... ... ..18mg
-lactose ... ... ... ... ... ... ... ... ... ... ... ... .55mg
-silica gel ... ... ... ... ... ... ... ... ... ... ... ... .1mg
-sodium starch glycolate ... ... ... ... ... ... ... ... ... ... ..10mg
-talcum powder ... ... ... ... ... ... ... ... ... ... ... ..10mg
-Magnesium Stearate ... ... ... ... ... ... ... ... ... ... ... 1mg
Embodiment B
The tablet that contains 50mg active ingredient and following component according to the usual method preparation:
-Shi (I) compound ... ... ... ... ... ... ... ... ... ... ... 50mg
-lactose ... ... ... ... ... ... ... ... ... ... ... ..104mg
-Mierocrystalline cellulose ... ... ... ... ... ... ... ... ... ... ... 40mg
-polyvidone ... ... ... ... ... ... ... ... ... ... ... 10mg
-sodium starch glycolate ... ... ... ... ... ... ... ... ... ... 22mg
-talcum powder ... ... ... ... ... ... ... ... ... ... ... 10mg
-Magnesium Stearate ... ... ... ... ... ... ... ... ... ... .2mg
-silica gel ... ... ... ... ... ... ... ... ... ... ... ..2mg
The mixture of-Walocel MT 20.000PV, glycerine and titanium oxide (72/3.5/24.5) is an amount of
Every coating tablet 245mg
Embodiment C
Preparation comprises the Injectable solution of 10mg active result and following component:
-Shi (I) compound ... ... ... ... ... ... ... ... ... ... .10mg
-phenylformic acid ... ... ... ... ... ... ... ... ... ... ... 80mg
-phenylcarbinol ... ... ... ... ... ... ... ... ... ... ... 0.06ml
-Sodium Benzoate ... ... ... ... ... ... ... ... ... ... .80mg
-95% ethanol ... ... ... ... ... ... ... ... ... ... .0.4ml
-sodium hydroxide ... ... ... ... ... ... ... ... ... ... .24mg
-propylene glycol ... ... ... ... ... ... ... ... ... ... ... 1.6ml
-water ... ... ... ... ... ... ... ... ... ... .... in right amount to 4ml
The present invention also relates to prevent and treat the method for the disease that relates to the Protein tau phosphorylation by giving construction (I) compound and pharmacologically acceptable salt thereof.
Claims (14)
1. formula (I) compound:
Wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-1OC) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1, C (=NH) R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, heterocycle, formyl radical, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5, R6 and R7 are independently from each other following groups: halogen, CN, NO2, NH
2, OH, COOH, C (O) OR8 ,-O-C (O) R8, NR8R9, NHC (O) R8, C (O) NR8R9, NHC (S) R8, C (S) NR8R9, SR8, S (O) R8, SO
2R8, NHSO
2R8, SO
2NR8R9 ,-O-SO
2R8 ,-SO
2-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C) alkyl, (1-6C) alkoxyl group, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl group, adamantyl or multi-ring alkyl; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
R1, R2, R8, R9, R10 and R11 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group, heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, trifluoromethyl, trifluoromethoxy;
R1 and R2 or R8 and R9 or R10 and R11 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
And when R3 was 6-membered nitrogen-containing heteroaryl base or thiazolyl or imidazolyl Huo oxazolyl, at least one was an aryl unsubstituted or that replaced by one or more substituting groups in R5 and the R6 base, and described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
2. formula (I) compound:
Wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1, C (=NH) R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, heterocycle, formyl radical, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5 and R6 are independently from each other following groups: halogen, CN, NO
2, NH
2, OH, COOH, C (O) OR8 ,-O-C (O) R8, NR8R9, NHC (O) R8, C (O) NR8R9, NHC (S) R8, C (S) NR8R9, SR8, S (O) R8, SO
2R8, NHSO
2R8, SO
2NR8R9 ,-O-SO
2R8 ,-SO
2-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C) alkyl, (1-6C) alkoxyl group, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl group, adamantyl, multi-ring alkyl; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
R7 is halogen, methyl, cyclopropyl, CN, OH, methoxyl group, trifluoromethyl, vinyl, ethynyl, trifluoromethoxy, NO
2, NH
2Or NMe
2
R1, R2, R8, R9, R10 and R11 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, trifluoromethyl or trifluoromethoxy;
R1 and R2 or R8 and R9 or R10 and R11 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
And when R3 was 6-membered nitrogen-containing heteroaryl base or thiazolyl or imidazolyl Huo oxazolyl, at least one was an aryl unsubstituted or that replaced by one or more substituting groups in R5 and the R6 base, and described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR10, COOH, C (O) OR10 ,-O-C (O) R10, NR10R11, NHC (O) R10, C (O) NR10R11, NHC (S) R10, C (S) NR10R11, SR10, S (O) R10, SO
2R10, NHSO
2R10, SO
2NR10R11 ,-O-SO
2R10 ,-SO
2-O-R10, aryl, heteroaryl, formyl radical, trifluoromethyl, trifluoromethoxy or (1-6C) alkyl;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
3. formula (I) compound:
Wherein:
R3 be (1-6C) alkyl, aryl, aryl (1-6C) alkyl, heteroaryl, heteroaryl (1-6C) alkyl, with (1-10C) Cycloalkylfused aryl or heteroaryl, heterocycle, Heterocyclylalkyl, cycloalkyl, adamantyl, multi-ring alkyl, alkenyl, alkynyl group, CONR1R2, CSNR1R2, COOR1, SO
2R1 or C (=NH) NR1 base; These groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, formyl radical, oxo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl;
R5 is an aryl;
R6 and R7 are halogen, methyl, cyclopropyl, CN, OH, methoxyl group, trifluoromethyl, vinyl, ethynyl, trifluoromethoxy, NO independently of one another
2, NH
2Or NMe
2
R1 and R2 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy;
R1 and R2 can form 5-or the 6-unit ring that contains or do not contain heteroatoms such as O, S or N;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
4. claim 1 compound is selected from:
N-(two the ring [2.2.1] heptan-5-alkene-2-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3, the 3-dimethylbutyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3-phenyl propyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(cyclopropyl methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(cyclopentyl-methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-(methylthio group) propyl group]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(phenylethyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(cyclohexyl methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-propyl group-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(2,2,3,3,4,4,4-seven fluorine butyl)-5-phenyl-1H-indazole-3-amine hydrate;
6-chloro-7-fluoro-N-(4,4,4-trifluoro butyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(4-p-methoxy-phenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(phenyl methyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(4-cyano-phenyl) methyl]-5-phenyl-1H-indazole-3-amine;
The N-[(4-chloro-phenyl-) methyl]-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(3-p-methoxy-phenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[4-(trifluoromethoxy) phenyl] methyl]-5-phenyl-1H-indazole-3-amine;
N-[4-[[[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] amino] methyl] phenyl] ethanamide;
6-chloro-7-fluoro-N-[(3, the 5-dichlorophenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[4-(trifluoromethyl) phenyl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(4-fluorophenyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-(4-methylphenoxy) phenyl methyl]-5-phenyl-1H-indazole-3-amine;
N-(2,2,3,3,4,4,4-seven fluorine butyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[3, two (trifluoromethyl) phenyl of 5-] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[3-(trifluoromethyl) phenyl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(6-methoxyl group-2-naphthyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(pentafluorophenyl group) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[4-(methylthio group) phenyl] methyl]-5-phenyl-1H-indazole-3-amine;
N-[(4-chloro-3-fluorophenyl) methyl]-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(3,3, the 3-trifluoro propyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(3-thienyl methyl)-1H-indazole-3-amine;
N-(two the ring [2.2.1] heptan-5-alkene-2-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
N-(1,1 '-xenyl-4-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[4-(dimethylamino) phenyl] methyl]-5-phenyl-1H-indazole-3-amine;
N-(2,2 '-bithiophene-5-ylmethyl)-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[1-(phenyl methyl)-1H-imidazoles-2-yl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[1-methyl isophthalic acid H-imidazoles-2-yl] methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(1-Methyl-1H-indole-3-yl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(5-methyl-2-furyl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(1H-pyrroles-2-ylmethyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[(1H-imidazoles-2-yl) methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[(1H-imidazol-4 yl) methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(1H-pyrazole-3-yl methyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[2-methyl isophthalic acid H-imidazol-4 yl] methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[(3,5-dimethyl-1-phenyl-1H-pyrazoles-4-yl) methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[2-phenyl-1H-imidazol-4 yl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[[5-(4-chloro-phenyl-)-2-furyl] methyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[(1-methyl isophthalic acid H-pyrroles-2-yl) methyl]-1H-indazole-3-amine;
4-[5-[[[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] amino] methyl]-the 2-furyl]-benzsulfamide;
6-chloro-7-fluoro-5-phenyl-N-(3-thienyl methyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[[2-phenyl-1H-imidazol-4 yl] methyl]-1H-indazole-3-amine;
2-[[[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] amino] methyl]-5-(methylthio group)-1H-imidazoles-4-ethyl formate;
6-chloro-7-fluoro-5-phenyl-N-[[5-[4-(trifluoromethyl) phenyl]-the 2-furyl] methyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-[2-(piperidino) ethyl]-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[2-(4-morpholinyl) ethyl]-5-phenyl-1H-indazole-3-amine;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(3, the 5-dichlorophenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(2-propenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(phenyl methyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-Phenoxyphenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-p-methoxy-phenyl) methyl] urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-[4-(trifluoromethyl) phenyl] urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-p-methoxy-phenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-cyclohexyl urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-propyl group urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-chloro-phenyl-) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-fluorophenyl) urea;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-N '-(three ring [3.3.1.1
3,7] last of the ten Heavenly stems)-1-base urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-(4-aminomethyl phenyl) urea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-methyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-cyano group-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-cyclopropyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-hydroxyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-methoxyl group-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-trifluoromethyl-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-trifluoromethoxy-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-nitro-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-amino-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-dimethylamino-5-phenyl-1H-indazole-3-yl) urea;
N-(6-chloro-7-ethynyl-5-phenyl-1H-indazole-3-yl) urea;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-methyl-benzsulfamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] Toluidrin;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-2-third sulphonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-2,2,2-trifluoro ethyl sulfonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-the 2-thiophenesulfonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] benzsulfamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-(trifluoromethyl) benzsulfamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-5-(3-isoxazolyl)-2-thiophenesulfonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-fluorobenzene sulphonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-the 4-methoxybenzenesulphoismide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl] the benzene Toluidrin;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-1-methyl isophthalic acid H-imidazoles-4-sulphonamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-(1, the 1-dimethyl ethyl) benzsulfamide;
N-[4-[[(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl) amino] alkylsulfonyl] phenyl] ethanamide;
N-[6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl]-4-methylbenzene Toluidrin;
6-chloro-7-fluoro-N-(pentafluorophenyl group)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3, the 4-difluorophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(2,3,5,6-tetrafluoro phenyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-5-phenyl-N-(2,4, the 6-trifluorophenyl)-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(4-fluorophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-(trifluoromethyl) phenyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[4-(trifluoromethyl) phenyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-[3-fluoro-5-(trifluoromethyl) phenyl]-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(4-nitrophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3-nitrophenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(3-p-methoxy-phenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(4-p-methoxy-phenyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N, 5-phenylbenzene-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(1-pyridyl)-5-phenyl-1H-indazole-3-amine;
6-chloro-7-fluoro-N-(2-pyridyl)-5-phenyl-1H-indazole-3-amine;
N-butyl-6-chloro-7-fluoro-5-phenyl-1H-indazole-3-amine;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-N '-phenylurea;
N-(6-chloro-7-fluoro-5-phenyl-1H-indazole-3-yl)-3-methoxybenzenesulphoismide;
Its racemic modification, enantiomer or diastereomer and composition thereof, its tautomer and pharmacologically acceptable salt thereof.
5. the compound in the claim 1 or 2 is selected from:
Piperidines-1-formic acid (6,7-two fluoro-5-phenyl-1H-indazole-3-yl) acid amides;
Tetramethyleneimine-1-formic acid (6,7-two fluoro-5-phenyl-1H-indazole-3-yl) acid amides;
1-(6,7-two fluoro-5-phenyl-1H-indazole-3-yl)-3-[3-(4-methylpiperazine-1-yl) propyl group] urea;
Its tautomer and pharmacologically acceptable salt thereof.
6. be used for preparing each the compound of claim 1-5 of medicine.
7. pharmaceutical composition, this pharmaceutical composition contain among the claim 1-5 each compound in pharmaceutically acceptable medium.
8. the medicine of claim 7, this medicine contain among at least a claim 1-5 each compound, are used for the treatment of the disease that relates to the Protein tau phosphorylation.
9. the medicine of claim 6, this medicine contains among at least a claim 1-5 each compound, is used for the treatment of neurodegenerative disease, apoplexy, cranium and trauma of spinal cord and peripheral neuropathy, obesity, metabolic disease, type ii diabetes, essential hypertension, atherosclerotic cardiovascular disease, polycystic ovary syndrome, X syndrome, immune deficiency and cancer.
10. the medicine of claim 9, described neurodegenerative disease is Alzheimer, Parkinson's disease, os frontoparietale dementia, corticobasal degeneration or Pick's disease.
11. prepare the method for the defined formula of claim 1 (I) compound, wherein in formula (I), R3 is (1-6C) alkyl, aryl (1-6C) alkyl, heteroaryl (1-6C) alkyl, Heterocyclylalkyl, cycloalkyl or multi-ring alkyl, these groups are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, CN, NO
2, NH
2, OH, OR1, COOH, C (O) OR1 ,-O-C (O) R1, NR1R2, NHC (O) R1, C (O) NR1R2, SR1, S (O) R1, SO
2R1, NHSO
2R1, SO
2NR1R2, C (S) NR1R2, NHC (S) R1 ,-O-SO
2R1 ,-SO
2-O-R1, aryl, heteroaryl, formyl radical, oxo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy or (1-6C) alkyl and R1, R2 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another; they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy; Described method is included in the methylene dichloride, be that formula (I) derivative, R1CHO derivative and the sodium triacetoxy borohydride of H is prepared with R3 wherein, and resulting product does not transform or be converted into pharmacologically acceptable salt.
12. prepare the method for the defined formula of claim 1 (I) compound, wherein in formula (I), R3 is that CONR1R2 or CSNR1R2 and R1 and R2 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl independently of one another, they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy; Described method is included in the tetrahydrofuran (THF), adopt OCNR1 and wherein R3 be that formula (I) derivative of H is prepared, and resulting product does not transform or is converted into pharmacologically acceptable salt.
13. prepare the method for the defined formula of claim 1 (I) compound, wherein in formula (I), R3 is SO
2R1 and R1 are hydrogen, (1-6C) alkyl, aryl, alkenyl, alkynyl group or heteroaryl, and they itself are unsubstituted or by one or more substituting groups replacements, described substituting group is selected from halogen, (1-6C) alkyl, (1-6C) alkoxyl group, CN, NO
2, NH
2, OH, COOH, COO alkyl, CONH
2, formyl radical, oxo, trifluoromethyl or trifluoromethoxy; Described method is included in alkali and exists down, in methylene dichloride, uses SULPHURYL CHLORIDE R1SO
2Cl and wherein R3 be that formula (I) derivative of H is prepared, and resulting compound does not transform or is converted into pharmacologically acceptable salt.
14. midbody product, for:
6,7-two fluoro-1H-indazole-3-amine;
N-(6,7-two fluoro-1H-indazole-3-yls) butyramide:
N-[6,7-two fluoro-1-[[2-(three silyls) oxyethyl group] methyl]-1H-indazole-3-yl] butyramide;
N-[5-bromo-6,7-two fluoro-1-[[2-(three silyls) oxyethyl group] methyl]-1H-indazole-3-yl]-butyramide;
N-[6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-yl] butyramide;
6,7-two fluoro-5-phenyl-1-[[2-(three silyls) oxyethyl groups] methyl]-1H-indazole-3-amine;
6,7-two fluoro-5-phenyl-1H-indazole-3-amine.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0215720 | 2002-12-12 | ||
| FR0215720A FR2848554A1 (en) | 2002-12-12 | 2002-12-12 | New aminoindazole derivatives are kinase inhibitors, useful in the treatment of neurodegenerative diseases, obesity, metabolic disorders, diabetes, hypertension, polycystic ovarian syndrome, cancers and other disorders |
| US44463003P | 2003-02-04 | 2003-02-04 | |
| US60/444,630 | 2003-02-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA038256169A Division CN1713909A (en) | 2002-12-12 | 2003-09-03 | Aminoindazole derivatives and use thereof as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101979382A true CN101979382A (en) | 2011-02-23 |
Family
ID=32338720
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105043043A Pending CN101979382A (en) | 2002-12-12 | 2003-09-03 | Aminoindazole derivatives and use thereof as kinase inhibitors |
| CNA038256169A Pending CN1713909A (en) | 2002-12-12 | 2003-09-03 | Aminoindazole derivatives and use thereof as kinase inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA038256169A Pending CN1713909A (en) | 2002-12-12 | 2003-09-03 | Aminoindazole derivatives and use thereof as kinase inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JP4764168B2 (en) |
| CN (2) | CN101979382A (en) |
| AR (1) | AR041132A1 (en) |
| AT (1) | ATE520399T1 (en) |
| FR (1) | FR2848554A1 (en) |
| ME (1) | MEP25308A (en) |
| MY (1) | MY138085A (en) |
| PE (2) | PE20091629A1 (en) |
| RS (1) | RS20050421A (en) |
| TW (1) | TWI345561B (en) |
| ZA (1) | ZA200504681B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115260165A (en) * | 2021-04-29 | 2022-11-01 | 中国科学院上海药物研究所 | Benzo nitrogen-containing five-membered heterocyclic compounds and their synthesis and application |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007002717A1 (en) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclic indazole derivatives |
| DE102007022565A1 (en) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclic indazole derivatives |
| AU2010217629A1 (en) * | 2009-02-26 | 2011-09-15 | Glaxo Group Limited | Pyrazole derivatives used as CCR4 receptor antagonists |
| US10273252B2 (en) | 2015-06-15 | 2019-04-30 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole derivative |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51143010A (en) * | 1975-06-04 | 1976-12-09 | Kao Corp | Stable bleaching detergent composition |
| WO2002022608A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6593349B2 (en) * | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| CZ2004359A3 (en) * | 2001-09-26 | 2004-09-15 | Pharmacia Italia S.P.A. | Aminoindazole derivatives exhibiting kinase inhibitor activity, process of their preparation and pharmaceutical compositions in which the derivatives are comprised |
| FR2836915B1 (en) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | AMINOINDAZOLE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
| PL374946A1 (en) * | 2002-09-05 | 2005-11-14 | Aventis Pharma S.A. | Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same |
-
2002
- 2002-12-12 FR FR0215720A patent/FR2848554A1/en active Pending
-
2003
- 2003-09-01 PE PE2009001071A patent/PE20091629A1/en not_active Application Discontinuation
- 2003-09-01 PE PE2003000886A patent/PE20040996A1/en not_active Application Discontinuation
- 2003-09-03 CN CN2010105043043A patent/CN101979382A/en active Pending
- 2003-09-03 JP JP2005512867A patent/JP4764168B2/en not_active Expired - Fee Related
- 2003-09-03 ME MEP-253/08A patent/MEP25308A/en unknown
- 2003-09-03 AR ARP030103187A patent/AR041132A1/en unknown
- 2003-09-03 CN CNA038256169A patent/CN1713909A/en active Pending
- 2003-09-03 RS YUP-2005/0421A patent/RS20050421A/en unknown
- 2003-09-03 AT AT03769560T patent/ATE520399T1/en not_active IP Right Cessation
- 2003-09-04 TW TW092124409A patent/TWI345561B/en not_active IP Right Cessation
- 2003-09-04 MY MYPI20033346A patent/MY138085A/en unknown
-
2005
- 2005-06-08 ZA ZA200504681A patent/ZA200504681B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115260165A (en) * | 2021-04-29 | 2022-11-01 | 中国科学院上海药物研究所 | Benzo nitrogen-containing five-membered heterocyclic compounds and their synthesis and application |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI345561B (en) | 2011-07-21 |
| JP2006516266A (en) | 2006-06-29 |
| FR2848554A1 (en) | 2004-06-18 |
| CN1713909A (en) | 2005-12-28 |
| RS20050421A (en) | 2007-08-03 |
| ATE520399T1 (en) | 2011-09-15 |
| AR041132A1 (en) | 2005-05-04 |
| TW200422293A (en) | 2004-11-01 |
| JP4764168B2 (en) | 2011-08-31 |
| ZA200504681B (en) | 2006-08-30 |
| MY138085A (en) | 2009-04-30 |
| PE20040996A1 (en) | 2005-01-28 |
| PE20091629A1 (en) | 2009-11-16 |
| MEP25308A (en) | 2010-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW530046B (en) | Azetidine derivatives, their preparation and medicaments containing them | |
| JP5171918B2 (en) | Intermediate compounds for the synthesis of aminoindazole derivatives useful as kinase inhibitors | |
| RU2339624C2 (en) | Derivatives of aminoindazols and their application as kinases inhibitors | |
| CN1832928B (en) | 5-membered heterocycle-based p38 kinase inhibitors | |
| TW546297B (en) | Heterocyclic compounds as antiinflammatory agents and their making process, pharmaceutical composition containing the same and their uses | |
| TWI230153B (en) | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | |
| RU2345070C2 (en) | Aminoindazole derivatives as medications, method of their obtaining and pharmaceutical compositions containing them | |
| CN107001259B (en) | Substituted azetidine derivatives as TAAR ligands | |
| CN101039904B (en) | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor | |
| JP2010006813A (en) | Use of gal3 receptor antagonist for treating depression and/or anxiety, and compound for use in such method | |
| CN102781914A (en) | Indole derivative | |
| CN101979382A (en) | Aminoindazole derivatives and use thereof as kinase inhibitors | |
| FR2911136A1 (en) | New N-(4-cyano-1H-pyrazol-3-yl)-methylamine derivatives, are cannabinoid CB1 receptor antagonists, useful e.g. for treating psychiatric, neurodegenerative or metabolic disorders | |
| CN101421264A (en) | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | |
| AU2020343585A1 (en) | Chronic kidney disease treatment or prevention method | |
| CN1982316A (en) | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | |
| FR2888236A1 (en) | New N-(1,5-diphenyl-1H-pyrazol-3-yl)methylsulfonamide derivatives, useful to treat/prevent e.g. appetite disorders, metabolic disorders, gastrointestinal disorders and inflammatory disorders, are cannabinoids receptor antagonists | |
| HK1101080A (en) | Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same | |
| HK1235395A1 (en) | Substituted azetidine derivatives as taar ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110223 |